{
  "questions": [
    {
      "exact_answer": [
        [
          "sofosbuvir"
        ],
        [
          "Magnesium Cation"
        ],
        [
          "Hepatitis C virus"
        ],
        [
          "Sovaldi"
        ],
        [
          "Singular"
        ],
        [
          "Film-coated tablet"
        ],
        [
          "Polymerase"
        ],
        [
          "Inhibitor"
        ],
        [
          "Preposition For"
        ],
        [
          "Aftercare"
        ],
        [
          "Employer"
        ],
        [
          "\u003c90"
        ],
        [
          "Tablet Dosing Unit"
        ],
        [
          "economic availability or accessibility"
        ],
        [
          "European Union"
        ],
        [
          "Approved"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Chinese Language"
        ],
        [
          "Treatment Protocols"
        ],
        [
          "Options"
        ],
        [
          "Healthy Volunteers"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Health Care Costs"
        ],
        [
          "Introduction procedure"
        ],
        [
          "Improving (qualifier value)"
        ],
        [
          "Contain (action)"
        ],
        [
          "Cost Effectiveness"
        ],
        [
          "Infected"
        ],
        [
          "Oral"
        ],
        [
          "Administration, Oral"
        ],
        [
          "Status post"
        ],
        [
          "Post"
        ],
        [
          "Application procedure"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Sensitive"
        ],
        [
          "Methods"
        ],
        [
          "Factor"
        ],
        [
          "Patients"
        ]
      ],
      "id": "5896deff78275d0c4a000013",
      "ideal_answer": "Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus?. After the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C, employers have become very sensitive to new, and especially unforeseen, factors that significantly raise healthcare costs. The developed method was applied to the analysis of the two drugs after a single oral administration of Harvoni 400/90 mg film-coated tablets containing 400 mg sofosbuvir and 90 mg ledipasvir to four healthy volunteers. The single-tablet regimen of the hepatitis C virus (HCV) NS5A inhibitor ledipasvir and the HCV NS5B polymerase inhibitor sofosbuvir (ledipasvir/sofosbuvir; Harvoni(®)) was recently approved in the US and the EU. Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. "
    },
    {
      "exact_answer": [
        [
          "Epigenomics"
        ],
        [
          "Data"
        ],
        [
          "NIH Roadmap Initiative tag"
        ],
        [
          "Server (computer)"
        ],
        [
          "Choose (action)"
        ],
        [
          "Filters"
        ],
        [
          "Geographic Locations"
        ],
        [
          "Encode (action)"
        ],
        [
          "Software Development"
        ],
        [
          "Project"
        ],
        [
          "Interface Device Component"
        ],
        [
          "Depth"
        ],
        [
          "Comprehensive"
        ],
        [
          "Providing (action)"
        ],
        [
          "Experimental Finding"
        ],
        [
          "Set scale"
        ],
        [
          "Containing (qualifier)"
        ],
        [
          "Major"
        ],
        [
          "Data Analysis"
        ]
      ],
      "id": "588fd8f3621ea6ff7e000001",
      "ideal_answer": "It contains data from four major epigenome projects, namely ENCODE, ROADMAP, BLUEPRINT and DEEP. Here we present the DeepBlue Epigenomic Data Server, which streamlines epigenomic data analysis as well as software development. DeepBlue provides a comprehensive programmatic interface for finding, selecting, filtering, summarizing and downloading region sets. "
    },
    {
      "exact_answer": "yes",
      "id": "58a2da4260087bc10a000005",
      "ideal_answer": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance. Study of the deficiency pattern amongst family members of the enzyme deficient subjects confirmed the X-linked inheritance of G-6-PD deficiency. Severe red cell glucose-6-phosphate dehydrogenase (G-6-PD) deficiency has been found in an \u0027aboriginal\u0027 Finnish family. 2 male and 9 female carriers of the variant G-6-PD were studied. The investigation of the patient\u0027s whole family showed the typical recessive X-linked inheritance of this enzyme-defect. The genetic pattern is consistent with x-linked recessive inheritance and the defect is associated with drug (primaquine) induced haemolysis. After having described in detail the pathophysiology, symptomatology, X-chromosomal inheritance and some laboratory methods in detecting G-6-PD-deficiency by demonstrating a case of favism (Schulz et al. 1977), the authors now discuss the particularities of the enzyme deficiency in the newborn. This was caused by Glucose-6-Phosphate-Dehydrogenase-Deficiency, which could be demonstrated by a red-cell-enzyme analysis. This genetic defect shows sex linked inheritance and a marked heterogeneity. G6PD deficiency is the most common enzymopathy in the world. Frequency and clinical manifestations of this defect are discussed. "
    },
    {
      "id": "58a3261e60087bc10a00000c",
      "ideal_answer": "Taken together, our results provided new evidence for the effectiveness of EGCG in vitiligo treatment and supported JAK2 as a molecular target for vitiligo medicine development. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA. Efficacy and safety data suggest that some of these oral Jak inhibitors as well as their topical formulations may soon enter the daily clinical practice for treating patients with psoriasis, lupus erythematosus or other inflammatory skin diseases. Jaks have recently gained significant attention as therapeutic targets in inflammation and autoimmunity, and several Jak inhibitory small molecules have been developed. "
    },
    {
      "exact_answer": [
        [
          "solanezumab"
        ],
        [
          "Antibodies"
        ],
        [
          "crenezumab"
        ],
        [
          "suggestion"
        ],
        [
          "Presenile dementia"
        ]
      ],
      "id": "58a95c711978bbde22000001",
      "ideal_answer": "Most importantly, recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence. Aducanumab is an anti-Aβ antibody being developed for the treatment of AD, and interim analyses of a phase 1b clinical trial have suggested potential beneficial effects on the amyloid pathology and the cognitive status in patients treated with aducanumab. The antibody aducanumab reduces Aβ plaques in Alzheimer\u0027s disease. ecent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. "
    },
    {
      "exact_answer": "yes",
      "id": "5884793ce56acf5176000008",
      "ideal_answer": "Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. This article summarizes the milestones in the development of migalastat leading to this first approval in the EU for the long-term treatment of adults and adolescents aged ≥16 years with a confirmed diagnosis of Fabry disease. Migalastat, an oral pharmacological chaperone being developed as an alternative to intravenous enzyme replacement therapy (ERT), stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. CONCLUSIONS: Migalastat offers promise as a first-in-class oral monotherapy alternative treatment to intravenous ERT for patients with Fabry disease and amenable mutations. Migalastat (Galafold™)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. "
    },
    {
      "exact_answer": [
        [
          "Peak level"
        ],
        [
          "Replicate"
        ],
        [
          "Accurate (qualifier)"
        ],
        [
          "Resolution"
        ],
        [
          "Width"
        ]
      ],
      "id": "587f760792a5b8ad44000005",
      "ideal_answer": "We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. In addition, JAMM\u0027s replicate integration improves peak spatial resolution, sorting and peak finding accuracy. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. "
    },
    {
      "exact_answer": [
        [
          "Toxic Epidermal Necrolysis"
        ],
        [
          "Schwartz-Jampel Syndrome"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Skin Specimen"
        ],
        [
          "Skin drug side effect"
        ],
        [
          "Spectrum"
        ],
        [
          "Mucous Membrane"
        ],
        [
          "Stevens-Johnson Syndrome"
        ],
        [
          "Detachment psychological"
        ],
        [
          "consider"
        ],
        [
          "Acute Generalized Exanthematous Pustulosis"
        ],
        [
          "Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum"
        ],
        [
          "Epidermolysis"
        ],
        [
          "Dermatologic disorders"
        ],
        [
          "Singular"
        ],
        [
          "Patch Tests"
        ],
        [
          "Cutaneous Route of Drug Administration"
        ],
        [
          "Extensive"
        ],
        [
          "Adverse reactions"
        ],
        [
          "Adverse reaction to drug"
        ],
        [
          "Extent"
        ],
        [
          "Skin"
        ],
        [
          "Aim (idea)"
        ],
        [
          "Current (present time)"
        ],
        [
          "Study"
        ]
      ],
      "id": "58a45d6060087bc10a00001d",
      "ideal_answer": "Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes. Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are diseases within the spectrum of severe cutaneous adverse reactions affecting skin and mucous membranes. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are considered part of a spectrum of adverse cutaneous drug reactions showing severe and extensive skin detachment. Currently, TEN and SJS are considered to be two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only by their extent of skin detachment. Our aim was to study patch testing in severe cutaneous adverse drug reactions (ADRs) (Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and other cutaneous ADRs). "
    },
    {
      "exact_answer": [
        [
          "Thalidomide"
        ],
        [
          "NPNT gene"
        ],
        [
          "Unresponsive to Treatment"
        ],
        [
          "POEMS Syndrome"
        ],
        [
          "Inflammatory Bowel Diseases"
        ],
        [
          "pomalidomide"
        ],
        [
          "lenalidomide"
        ],
        [
          "Pharmacy (field)"
        ],
        [
          "Clinical Trials, Randomized"
        ],
        [
          "Child"
        ],
        [
          "Analysis"
        ],
        [
          "M Protein, multiple myeloma"
        ],
        [
          "Clinical"
        ],
        [
          "Recombinant Vascular Endothelial Growth Factor"
        ],
        [
          "TRICHOHEPATOENTERIC SYNDROME"
        ],
        [
          "Arabic numeral 31"
        ],
        [
          "Plasma cell dyscrasia"
        ],
        [
          "Medical Specialities"
        ],
        [
          "Forecast of outcome"
        ],
        [
          "Intestines"
        ],
        [
          "Relieving"
        ],
        [
          "Polyneuropathy"
        ],
        [
          "Blinded"
        ],
        [
          "Infrequent"
        ],
        [
          "Multiple Myeloma"
        ],
        [
          "Japanese race"
        ],
        [
          "Preclinical"
        ],
        [
          "Weekly"
        ],
        [
          "Endocrine System Diseases"
        ],
        [
          "Mucosal lesions"
        ],
        [
          "Intestinal Mucosa"
        ],
        [
          "Receive"
        ],
        [
          "Introduction procedure"
        ],
        [
          "Retrospective Studies"
        ],
        [
          "Severity of illness"
        ],
        [
          "Death Related to Adverse Event"
        ],
        [
          "Lesion"
        ],
        [
          "Pregnancy Related Skin Change"
        ],
        [
          "Controlled Clinical Trial [Publication Type]"
        ],
        [
          "Safety Study"
        ],
        [
          "therapeutic aspects"
        ],
        [
          "Therapeutic Intervention"
        ],
        [
          "Systemic disease"
        ],
        [
          "Double Value Type"
        ],
        [
          "Clinical Trials"
        ],
        [
          "Efficacy Study"
        ],
        [
          "Stage level 3"
        ],
        [
          "Evaluation"
        ],
        [
          "Aim (idea)"
        ],
        [
          "Better"
        ],
        [
          "Symptoms"
        ],
        [
          "Before values"
        ],
        [
          "Methods"
        ],
        [
          "Clinical Research"
        ],
        [
          "Diagnosis Study"
        ],
        [
          "Large"
        ],
        [
          "Performed"
        ],
        [
          "Associated with"
        ],
        [
          "Patients"
        ],
        [
          "Study"
        ],
        [
          "Pre-study"
        ]
      ],
      "id": "58a0da5278275d0c4a000054",
      "ideal_answer": "However, no randomised clinical trial has been performed because of the rarity and severity of the disease.METHODS AND ANALYSIS: The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome. Thalidomide could relieve clinical symptoms and intestinal mucosal lesions effectively in children with refractory inflammatory bowel disease (IBD) from the pre-clinical study. In this retrospective study, pharmacy claims were analyzed for those patients with a diagnosis of MM who received thalidomide, lenalidomide, or pomalidomide from a large specialty pharmacy in the US between January 1, 2011, and December 31, 2013. Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome is a fatal systemic disorder associated with plasma cell dyscrasia and the overproduction of the vascular endothelial growth factor (VEGF). Recently, the prognosis of POEMS was substantially improved by introduction of therapeutic intervention for myeloma. "
    },
    {
      "exact_answer": [
        [
          "Paneth Cells"
        ],
        [
          "Crypt"
        ],
        [
          "Base"
        ],
        [
          "Intestinal crypt of Lieberkuhn"
        ],
        [
          "HUMANIN gene"
        ]
      ],
      "id": "58a9bbe81978bbde22000007",
      "ideal_answer": "The intestinal stem cell niche comprises both epithelial cells, in particular the Paneth cell,. resence of Paneth cells at the bottom of the crypts of Lieberkühn. Paneth cells (crypt base columnar cells (CBCCs)). Paneth cells at the crypt base. Paneth cells have been reported in colorectal adenomas and adenocarcinomas;. injury to Paneth cells (PCs) in the intestinal crypts. "
    },
    {
      "exact_answer": "yes",
      "id": "58848a13e56acf517600000d",
      "ideal_answer": "Regorafenib has been approved for third-line therapy. Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. DISCUSSION: The design of this trial allows an assessment of regorafenib activity over placebo in four sarcoma strata and might provide evidence for launching a phase III trial. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). Currently, regorafenib is examined in several clinical trials (mostly phase II) in different tumor entities, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and soft tissue sarcoma (STS). Thus, the Phase III studies with pazopanib, regorafenib, muramyl tripeptide (MTP) and ridaforolimus are extensively discussed as well as the biological rationale for the use of these compounds. "
    },
    {
      "exact_answer": [
        [
          "Somatomedins"
        ],
        [
          "Peptide Hydrolases"
        ],
        [
          "Proteins"
        ],
        [
          "Biochemical Pathway"
        ],
        [
          "Electron Transport Complex I"
        ],
        [
          "Genes"
        ],
        [
          "hGH Gene"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "MicroRNA Gene"
        ],
        [
          "Exhibits as Topic"
        ],
        [
          "Reproduction"
        ],
        [
          "Encode (action)"
        ],
        [
          "Immunity"
        ],
        [
          "Coding"
        ],
        [
          "Biological Evolution"
        ],
        [
          "Positive Selection"
        ],
        [
          "growth aspects"
        ],
        [
          "Metabolic Pathway"
        ],
        [
          "RNA Sequence"
        ],
        [
          "Rapid"
        ],
        [
          "genetic association"
        ],
        [
          "Evidence of"
        ],
        [
          "Factor"
        ],
        [
          "Observed"
        ]
      ],
      "id": "58839d892305cd7e21000006",
      "ideal_answer": "In addition, both protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution. We observed positive selection in growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I genes (metabolic pathways), and genes encoding immunobiological factors and proteases (reproductive and immunity pathways). "
    },
    {
      "exact_answer": [
        [
          "Beta thalassemia trait"
        ],
        [
          "Greeks"
        ],
        [
          "Hemoglobinopathies"
        ],
        [
          "Greece"
        ],
        [
          "shared attribute"
        ]
      ],
      "id": "58a2df9c60087bc10a000006",
      "ideal_answer": "Hemoglobinopathies are very common in Greece, the incidence of beta-thalassemia trait being 8% and that of sickle cell trait ranging from 1 to 32% in various districts. No statistically significant differences were found in the frequency of beta-thalassaemia trait between control subjects (8.49%) and the whole Greek population. "
    },
    {
      "exact_answer": [
        [
          "Contrave"
        ],
        [
          "Bupropion Hydrochloride"
        ],
        [
          "Naltrexone hydrochloride"
        ],
        [
          "Extended Release Dosage Form"
        ],
        [
          "combination of objects"
        ]
      ],
      "id": "58a32edd60087bc10a000012",
      "ideal_answer": "Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity. "
    },
    {
      "id": "58a8a51b7f77222767000001",
      "ideal_answer": "CPEB (Cytoplasmic Polyadenylation Element Binding) proteins are a family of four RNA-binding proteins that regulate the translation of maternal mRNAs controlling meiotic cell cycle progression. The family of cytoplasmic polyadenylation element binding proteins CPEB1, CPEB2, CPEB3, and CPEB4 binds to the 3\u0027-untranslated region (3\u0027-UTR) of mRNA, and plays significant roles in mRNA metabolism and translation regulation. This cytoplasmic polyadenylation element (CPE) is the binding platform for CPE-binding protein (CPEB), which promotes polyadenylation-induced translation. "
    },
    {
      "exact_answer": [
        [
          "fulvestrant"
        ],
        [
          "Tamoxifen"
        ],
        [
          "ESR1 gene"
        ],
        [
          "Estrogen Receptors"
        ],
        [
          "Malignant neoplasm of breast"
        ],
        [
          "Preposition For"
        ],
        [
          "Estrogens"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "ICI 182780"
        ],
        [
          "Toremifene"
        ],
        [
          "exemestane"
        ],
        [
          "anastrozole"
        ],
        [
          "Hormone Receptor"
        ],
        [
          "letrozole"
        ],
        [
          "Raloxifene"
        ],
        [
          "Receptors, Steroid"
        ],
        [
          "Bioavailable"
        ],
        [
          "Singular"
        ],
        [
          "Xenograft procedure"
        ],
        [
          "Selective Estrogen Receptor Modulators"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Selective Estrogen Receptor Down Regulator"
        ],
        [
          "Robust"
        ],
        [
          "Negation"
        ],
        [
          "Positive Finding"
        ],
        [
          "Advanced phase"
        ],
        [
          "literary novel"
        ],
        [
          "Oral"
        ],
        [
          "Evaluation"
        ],
        [
          "Aromatase Inhibitors [MoA]"
        ],
        [
          "Current (present time)"
        ],
        [
          "Treatment intent"
        ],
        [
          "Recommendation"
        ],
        [
          "Guideline [Publication Type]"
        ],
        [
          "Pharmacologic Substance"
        ],
        [
          "Metastatic malignant neoplasm to brain"
        ],
        [
          "Malignant neoplasm of female breast"
        ],
        [
          "The science and art of healing"
        ],
        [
          "Steroids"
        ],
        [
          "Approved"
        ],
        [
          "Biochemical turnover"
        ],
        [
          "Processed"
        ],
        [
          "Requirement"
        ],
        [
          "Refractory Carcinoma"
        ],
        [
          "Pharmacological assessment"
        ],
        [
          "Antagonist muscle action"
        ],
        [
          "status - In progress"
        ],
        [
          "Demonstrates"
        ],
        [
          "Woman"
        ],
        [
          "Targeted Therapy"
        ],
        [
          "Access"
        ],
        [
          "Small Molecule"
        ],
        [
          "Hormone Therapy"
        ],
        [
          "Resistant (qualifier value)"
        ],
        [
          "Female Breast Carcinoma"
        ],
        [
          "Breast"
        ],
        [
          "Identification (Psychology)"
        ],
        [
          "Efficacy Study"
        ],
        [
          "Activities"
        ],
        [
          "Therapy Evaluation"
        ],
        [
          "Target"
        ],
        [
          "Active"
        ],
        [
          "Brain"
        ],
        [
          "Potential"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "High risk of"
        ],
        [
          "Clinical"
        ],
        [
          "Patients"
        ],
        [
          "*Activity (kind of quantity)"
        ]
      ],
      "id": "58919aad621ea6ff7e00000d",
      "ideal_answer": "Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents. For women with hormone receptor-positive advanced breast cancer, endocrine therapies, including the selective estrogen receptor modulator tamoxifen, the aromatase inhibitors anastrozole, letrozole, and exemestane, and the selective estrogen receptor degrader fulvestrant, are recommended in clinical guidelines. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. Here we describe and characterize a novel, orally bioavailable small-molecule selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer. Tamoxifen, toremifene, and the selective estrogen receptor degrader fulvestrant are used to treat breast cancer, and tamoxifen and raloxifene protect against breast cancer in high-risk women. However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases. Currently, ICI 182,780 (ICI, fulvestrant) is the only SERD approved for the treatment of breast cancer. "
    },
    {
      "exact_answer": [
        [
          "Data"
        ],
        [
          "Cafe (environment)"
        ],
        [
          "Drug Packaging"
        ],
        [
          "DNA Microarray format"
        ],
        [
          "Chromosome Aberrations"
        ]
      ],
      "id": "5880a8ec0a76a87357000001",
      "ideal_answer": "CAFE: an R package for the detection of gross chromosomal abnormalities from gene expression microarray data. "
    },
    {
      "id": "58a5723c60087bc10a00001e",
      "ideal_answer": "To reduce peaks and rapid fluctuations of L-DOPA plasma levels (possibly responsible for peak-dose dyskinesias and end-of-dose deterioration) a slow-release formulation of L-DOPA in combination with benserazide or with benserazide plus catechol-O-methyltransferase inhibitors should be developed. L-DOPA in combination with benserazide or carbidopa constitutes the best available therapy for Parkinson\u0027s disease (PD). Recent human and animal biochemical investigations clearly confirm and extend previous findings indicating that benserazide is much more potent than carbidopa as peripheral decarboxylase inhibitor. "
    },
    {
      "id": "58a3423e60087bc10a000019",
      "ideal_answer": "Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, and fatal neurodegenerative disease affecting the central nervous system. Creutzfeldt-Jakob disease (sCJD) is the most prevalent of the human prion diseases, which are fatal and transmissible neurodegenerative diseases caused by the infectious prion protein (PrP(Sc). The origin of sCJD is unknown, although the initiating event is thought to be the stochastic misfolding of endogenous prion protein (PrP(C)) into infectious PrP(Sc). "
    },
    {
      "exact_answer": [
        [
          "DNA Transposable Elements"
        ],
        [
          "Melanosis"
        ],
        [
          "Introns"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Industry"
        ]
      ],
      "id": "58a877cf38c171fb5b000004",
      "ideal_answer": "Here we show that the mutation event giving rise to industrial melanism in Britain was the insertion of a large, tandemly repeated, transposable element into the first intron of the gene cortex. The industrial melanism mutation in British peppered moths is a transposable element. "
    },
    {
      "exact_answer": [
        [
          "daratumumab"
        ],
        [
          "elotuzumab"
        ],
        [
          "SLAMF7 gene"
        ],
        [
          "Ixazomib"
        ],
        [
          "Recombinant Immune Globulin"
        ]
      ],
      "id": "5880aef4c872c95565000001",
      "ideal_answer": "In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively. Of these agents, CD38-targeting antibodies have marked single agent activity in extensively pretreated MM, and preliminary results from studies with relapsed/refractory patients have shown enhanced therapeutic efficacy when daratumumab and isatuximab are combined with other agents. Daratumumab is a fully human anti-CD38 IgG1-κ monoclonal antibody (mAb) currently being evaluated in several Phase 2 and 3 clinical studies for the treatment of multiple myeloma (MM). Neutralization of the therapeutic CD38 antibody or CD38 denaturation on reagent red blood cells mitigates daratumumab interference with transfusion laboratory serologic tests. Dominantly daratumumab (anti-CD38) and elotuzumab (anti-CS1) showed extraordinary effectiveness in phase I/II trials. Furthermore, daratumumab, and probably also other CD38-targeting antibodies, interfere with blood compatibility testing and thereby complicate the safe release of blood products. "
    },
    {
      "id": "587f57f692a5b8ad44000002",
      "ideal_answer": "Both approaches converged to the conclusion that well-developed fractality is characteristic of elements that are either extremely conserved between species or are of ancient origin, i.e. conserved between distant organisms across evolution. We find widespread power-law-like distributions, i.e. linearity in double logarithmic scale, in the inter-CNE distances, a feature which is connected with fractality and self-similarity. We employed two methodologies: the scaling of block entropy and box-counting, with the aim to assess fractal characteristics of different CNE datasets. Conserved noncoding elements follow power-law-like distributions in several genomes as a result of genome dynamics. Fractality and entropic scaling in the chromosomal distribution of conserved noncoding elements in the human genome. We explored the chromosomal distribution of different classes of CNEs in the human genome. "
    },
    {
      "exact_answer": [
        [
          "Aseptic Meningitis"
        ],
        [
          "Viral meningitis"
        ],
        [
          "Meningitis"
        ],
        [
          "Simplexvirus"
        ],
        [
          "Human Herpesvirus 2"
        ],
        [
          "Type - attribute"
        ],
        [
          "shared attribute"
        ],
        [
          "Human herpesvirus 1"
        ],
        [
          "Human herpesvirus 3"
        ],
        [
          "Suspected qualifier"
        ],
        [
          "Negation"
        ],
        [
          "Nervous system complication, unspecified"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Communicable Diseases"
        ],
        [
          "Etiology aspects"
        ],
        [
          "Primary herpes simplex infection of genitalia"
        ],
        [
          "West Nile viral infection"
        ],
        [
          "Basin"
        ],
        [
          "Mediterranean"
        ],
        [
          "Encephalitis"
        ],
        [
          "Disease Outbreaks"
        ],
        [
          "Western Australia"
        ],
        [
          "Mental Suffering"
        ],
        [
          "Exist"
        ],
        [
          "Herpesviridae"
        ],
        [
          "In Cerebrospinal Fluid"
        ],
        [
          "Bacterial"
        ],
        [
          "Evaluation"
        ],
        [
          "Epstein-Barr Virus"
        ],
        [
          "Experimental Result"
        ],
        [
          "Detected (finding)"
        ],
        [
          "Benign multirecurrent endothelioleukocytal meningitis"
        ],
        [
          "Circumferential Supracrestal Fiberotomy"
        ],
        [
          "Preposition For"
        ],
        [
          "Patients"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "Parechovirus"
        ],
        [
          "Etiology"
        ],
        [
          "Associated with"
        ],
        [
          "Epidermodysplasia Verruciformis"
        ],
        [
          "Herpesviridae Infections"
        ],
        [
          "Case (situation)"
        ],
        [
          "Psyche structure"
        ],
        [
          "Case unit dose"
        ],
        [
          "Echovirus 6, Human"
        ],
        [
          "Echovirus Infections"
        ],
        [
          "Echovirus meningitis"
        ],
        [
          "Echovirus 9"
        ],
        [
          "Echovirus"
        ],
        [
          "Culicidae species"
        ],
        [
          "Algeria"
        ],
        [
          "Human rhinovirus A"
        ],
        [
          "Human rhinovirus"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Malawi"
        ],
        [
          "Integer +2"
        ],
        [
          "Flavivirus"
        ],
        [
          "Croatia"
        ],
        [
          "Mumps"
        ],
        [
          "Enterovirus"
        ],
        [
          "virologic"
        ],
        [
          "Confidentiality - sensitive"
        ],
        [
          "Meningeal"
        ],
        [
          "Septicemia"
        ],
        [
          "Cryptococcus"
        ],
        [
          "Study"
        ],
        [
          "West Nile Virus Pathway"
        ],
        [
          "Autumn"
        ],
        [
          "Money or percentage indicator - Percentage"
        ],
        [
          "Divide"
        ],
        [
          "metropolitan area"
        ],
        [
          "Serous"
        ],
        [
          "With - dosing instruction fragment"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Abnormally high"
        ],
        [
          "Stool specimen"
        ],
        [
          "Spain"
        ],
        [
          "Generic Role"
        ],
        [
          "Sterile (qualifier value)"
        ],
        [
          "Cytomegalovirus"
        ],
        [
          "Recurrent meningitis"
        ],
        [
          "Echo (insect)"
        ],
        [
          "Reverse Transcriptase Polymerase Chain Reaction"
        ],
        [
          "Confirmation"
        ],
        [
          "Rating (action)"
        ],
        [
          "User Group"
        ],
        [
          "Sporadic"
        ],
        [
          "Geographic Locations"
        ],
        [
          "geographic population"
        ],
        [
          "Links List"
        ],
        [
          "Herpes"
        ],
        [
          "Kind of quantity - Frequency"
        ],
        [
          "Problems - What subject filter"
        ],
        [
          "Epidemiology"
        ],
        [
          "Transmitted by"
        ],
        [
          "Infant, Newborn"
        ],
        [
          "Pathogenic organism"
        ],
        [
          "Immunoglobulin measurement"
        ],
        [
          "Tuberculosis"
        ],
        [
          "Records"
        ]
      ],
      "id": "589aec4778275d0c4a000037",
      "ideal_answer": "Aseptic meningitis is the most common type of meningitis and is characterized by meningeal inflammation that is not linked to identifiable bacterial pathogens in cerebrospinal fluid (CSF). Bearing in mind the high percentage of neurological complications found to exist in the most recent outbreaks of WNV infections recorded in the Mediterranean Basin (Bucharest, Algeria), it can be thought that the WNV plays some role in the factors contributing to viral meningitis and encephalitis which occur within the population of the areas at risk within Spain. During the autumn of 1992, Western Australia experienced a large viral meningitis outbreak of dual aetiology. Results confirm that EV-specific RT-PCR can detect HRVs, and at a practical level, identify potential problems of interpretation if fecal samples are used for surrogate screening in cases of suspected viral meningitis. The West Nile Virus (WNV) is a Flavivirus which is transmitted to man by means of different species of mosquitoes and causes outbreaks and sporadic cases of illness in different regions of the Old World, including the Mediterranean Basin. Compared with other types of viral meningitis, HSV-2-meningitis is associated with a significant rate of neurological complications in the acute stage. "
    },
    {
      "exact_answer": [
        [
          "Metformin"
        ],
        [
          "Sulfonylurea Compounds"
        ],
        [
          "Lixisenatide"
        ],
        [
          "exenatide"
        ],
        [
          "Blood Glucose"
        ],
        [
          "SLC5A2 gene"
        ],
        [
          "Iodides"
        ],
        [
          "GLP-1 Mimetics"
        ],
        [
          "Dipeptidyl Peptidase 4 Inhibitors [MoA]"
        ],
        [
          "Exertion"
        ],
        [
          "Positioning Attribute"
        ],
        [
          "shared attribute"
        ],
        [
          "Stretching exercises"
        ],
        [
          "Choose (action)"
        ],
        [
          "Pharmacologic Substance"
        ],
        [
          "Market"
        ],
        [
          "Worse"
        ],
        [
          "Line Specimen"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Decade"
        ],
        [
          "control substance"
        ],
        [
          "GLP-1 Receptor Agonist [EPC]"
        ],
        [
          "Availability of"
        ],
        [
          "Drug Kinetics"
        ],
        [
          "Dipeptidyl-Peptidase IV Inhibitors"
        ],
        [
          "Numbers"
        ],
        [
          "History of previous events"
        ],
        [
          "Secondary to"
        ],
        [
          "Second Line Treatment"
        ],
        [
          "Additional"
        ],
        [
          "Short Value"
        ],
        [
          "Inhibition"
        ],
        [
          "Current (present time)"
        ],
        [
          "Drug Control"
        ],
        [
          "year"
        ],
        [
          "ZGLP1 gene"
        ],
        [
          "Patients"
        ]
      ],
      "id": "58a0c09778275d0c4a000052",
      "ideal_answer": "After a decade-long effort to improve the pharmacokinetics of GLP1, a number of GLP1 analogues are currently available on the market. Sulphonylurea (SU) drugs have a history stretching back over 60 years, and have traditionally been the mainstay choice as second-line agents to be added to metformin once glycaemic control with metformin monotherapy deteriorates;. In 2013, sulfonylureas were the most common second-line treatment after metformin i. achieved by selectively inhibiting sodium-glucose co-transporter 2 (SGLT2). Dipeptidyl peptidase 4 (DPP-4) inhibitors are glycemic control drugs commonly used in T2DM patients. short-acting glucagon-like peptide-1 receptor agonists exenatide and lixisenatide. this position was taken by DPP-4 inhibitors. "
    },
    {
      "id": "58a9d3cd396a458e50000004",
      "ideal_answer": "Eteplirsen (Exondys 51) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics. By the method of exon skipping in dystrophin pre-mRNA the reading frame is restored and the internally deleted but functional dystrophin is produced. This approach uses antisense oligonucleotides (AONs) to modulate pre-mRNA splicing of dystrophin transcripts to restore the disrupted DMD reading frame. We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.) injection. Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping. Restoration of the open reading frame of the DMD gene and dystrophin protein production in Duchenne muscular dystrophy (DMD) can be achieved by exon skipping using antisense oligomers (AOs) targeted to splicing elements. "
    },
    {
      "exact_answer": [
        [
          "CD274 gene"
        ],
        [
          "Homo sapiens"
        ],
        [
          "IgG1"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ],
        [
          "Monoclonal Antibodies"
        ]
      ],
      "id": "5884c72fe56acf517600000f",
      "ideal_answer": "Several drugs targeting PD-1 (pembrolizumab and nivolumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved or are in the late stages of development. We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction. In addition, we assessed the safety and biological activity of a human anti-PD-L1 antibody (Avelumab) in chronically SIV-infected rhesus macaques. These studies thus provide an additional mode of action for an anti-PD-L1 mAb and support the rationale for further studies to enhance avelumab-mediated ADCC activity. Here, we describe the efficacy of NIR-PIT, using fully human IgG1 anti-PD-L1 monoclonal antibody (mAb), avelumab, conjugated to the photo-absorber, IR700DX, in a PD-L1 expressing H441 cell line, papillary adenocarcinoma of lung. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. We assessed treatment with avelumab, an anti-PD-L1 monoclonal antibody, in patients with stage IV Merkel cell carcinoma that had progressed after cytotoxic chemotherapy. "
    },
    {
      "id": "5881f0f1713cbdfd3d000004",
      "ideal_answer": "The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair. Ku70-binding protein 5 (Kub5)-Hera (K-H)/RPRD1B maintains genetic integrity by concomitantly minimizing persistent R-loops and promoting repair of DNA double strand breaks (DSBs). "
    },
    {
      "exact_answer": [
        [
          "Tacrine"
        ],
        [
          "Cholinesterase Inhibitors"
        ],
        [
          "Alzheimer\u0027s Disease Pathway KEGG"
        ],
        [
          "aspects of adverse effects"
        ],
        [
          "Phosphatidylcholines"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Diarrhea"
        ],
        [
          "Withdraw (activity)"
        ],
        [
          "Galantamine"
        ],
        [
          "rivastigmine"
        ],
        [
          "donepezil"
        ],
        [
          "Phosphatidylinositols"
        ],
        [
          "Acetylcholine"
        ],
        [
          "Mitochondria"
        ],
        [
          "Hepatotoxicity"
        ],
        [
          "Bioenergetics"
        ],
        [
          "Acetylcholinesterase"
        ],
        [
          "Extensive"
        ],
        [
          "gastrointestinal"
        ],
        [
          "Experimental Result"
        ],
        [
          "Withdrawal (dysfunction)"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Adverse effects"
        ],
        [
          "Anorexia"
        ],
        [
          "Nausea"
        ],
        [
          "Vomiting"
        ],
        [
          "Analog"
        ],
        [
          "Major"
        ],
        [
          "Benefits"
        ],
        [
          "Basic Research"
        ],
        [
          "physiological aspects"
        ],
        [
          "Clinical"
        ],
        [
          "Alzheimer\u0027s Disease Assessment Scale-Cognitive CDISC Version Questionnaire"
        ],
        [
          "Preposition For"
        ],
        [
          "Phosphatidylserines"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Associated with"
        ],
        [
          "Somalia"
        ],
        [
          "Placebos"
        ],
        [
          "Dyspepsia"
        ],
        [
          "Singular"
        ],
        [
          "Dizziness Adverse Event"
        ],
        [
          "shared attribute"
        ],
        [
          "Discontinued"
        ],
        [
          "Abnormally high"
        ],
        [
          "Abnormally low (qualifier value)"
        ],
        [
          "Acetylcholinesterase Inhibitors"
        ],
        [
          "Infrequent"
        ],
        [
          "Firstly"
        ],
        [
          "Malnutrition"
        ],
        [
          "compromise"
        ],
        [
          "Dietary Phosphatidylinositol"
        ],
        [
          "Cognition"
        ],
        [
          "Basis - conceptual entity"
        ],
        [
          "The science and art of healing"
        ],
        [
          "Odds Ratio"
        ],
        [
          "Specimen Type - Serum"
        ],
        [
          "Approved"
        ],
        [
          "Indication of (contextual qualifier)"
        ],
        [
          "Abundance"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Disruption"
        ],
        [
          "Assessment section"
        ],
        [
          "Elevation"
        ],
        [
          "N-(3-N-(benzyloxycarbonyl)amino-1-carboxypropyl)leucyl-O-methyltyrosine N-methylamide"
        ],
        [
          "Chloride Ion"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Etiology aspects"
        ],
        [
          "Changed status"
        ],
        [
          "Percent inhibition"
        ],
        [
          "Oxidation"
        ],
        [
          "Labeled (qualifier)"
        ],
        [
          "Adverse event"
        ],
        [
          "Weight Loss Adverse Event"
        ],
        [
          "Toxic liver disease"
        ],
        [
          "Abdominal Pain"
        ],
        [
          "Providing (action)"
        ],
        [
          "Mild to moderate"
        ],
        [
          "Numerous"
        ],
        [
          "Case unit dose"
        ],
        [
          "Finding of liver enzyme levels"
        ],
        [
          "Positive Finding"
        ],
        [
          "Profile (lab procedure)"
        ],
        [
          "Frequent"
        ],
        [
          "Clinical Trial [Publication Type]"
        ],
        [
          "Efficiency"
        ],
        [
          "Measurement of liver enzyme"
        ],
        [
          "Elevated liver enzymes"
        ],
        [
          "Daily"
        ],
        [
          "Induce (action)"
        ],
        [
          "Extent"
        ],
        [
          "Clinical Trials"
        ],
        [
          "Leading"
        ],
        [
          "Now (temporal qualifier)"
        ],
        [
          "Purpose"
        ],
        [
          "Efficacy Study"
        ],
        [
          "incidence of cases"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Relative"
        ]
      ],
      "id": "58a2fac960087bc10a000009",
      "ideal_answer": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. Gastrointestinal side effects (diarrhoea, anorexia, dyspepsia and abdominal pain) were the other major cause of adverse events and for withdrawal, and the odds ratio for withdrawal was also significantly different from one in favour of the control group (OR 3.8; 95%CI 2.8-5.1). In mild-to-moderate Alzheimer\u0027s disease, they all provide significant benefit versus placebo on the Alzheimer\u0027s Disease Assessment ScheduleCognitive Section (ADAS-Cog), Side effects, in 5% to 15% of cases, include nausea, vomiting, diarrhea, anorexia, and dizziness. Only one medication, tacrine, has been approved for its treatment, based on extensive basic research and positive results of several clinical trials. The antidementives are well tolerated and undesired effects are rare; except hepatotoxicity of tacrine and gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Its long-term benefits have yet to be determined and it has several adverse effects, including a tendency to increase liver enzymes to the extent that the medication has to be discontinued. "
    },
    {
      "id": "589c8e5e78275d0c4a000041",
      "ideal_answer": "Statins are inhibitors of HMG-CoA reductase, the enzyme that catalyzes the reduction of HMG-CoA to mevalonic acid by NADPH. Statins, which specifically inhibit HMG Co-A reductase, the rate-limiting step of cholesterol biosynthesis, are widely prescribed to reduce serum cholesterol and cardiac risk,. "
    },
    {
      "id": "58a989571978bbde22000002",
      "ideal_answer": "the first time after the discovery of ZIKV, the Brazilian scientists are studying the possibility for the virus to cause severe congenital infection related to microcephaly and serious birth defects due to the time-spatial coincidence of the alarming increase of newborns with microcephaly and the Brazilian ZIKV epidemic. the virus has been linked to congenital malformations, including microcephaly and other severe neurological diseases, such as Guillain-Barré syndrome. However, ZIKV infection in early pregnancy has been associated with severe birth defects, including microcephaly and other developmental issues. Although a causal relationship between Zika infection during pregnancy and microcephaly is strongly suspected, such a connection has not yet been scientifically proven. evidence suggests that congenital Zika virus infection is associated with microcephaly and other adverse pregnancy and infant outcomes. The current Zika virus (ZIKV) outbreak is associated with high numbers of human congenital birth defects. Zika virus (ZIKV) infection is a new emerging threat around the globe which might be responsible for microcephaly and Guillain-Barre syndrome in the infants. a convincing association between Zika virus infection during pregnancy and birth defects, like microcephaly, among some of the newborns. severe birth defects, such as microcephaly, have been linked to infection during early pregnancy. "
    },
    {
      "exact_answer": [
        [
          "Restless Legs Syndrome"
        ],
        [
          "Nociception"
        ],
        [
          "Familial"
        ],
        [
          "Child"
        ],
        [
          "Wedding"
        ]
      ],
      "id": "5891f9e549702f2e01000002",
      "ideal_answer": "Defining the phenotype of restless legs syndrome/Willis-Ekbom disease (RLS/WED): a clinical and polysomnographic study. With this retrospective cohort study, we aimed to determine the clinical and polysomnographic characteristics of 400 RLS/WED patients. Clinical features variability between familial and sporadic restless legs syndrome/Willis-Ekbom disease (RLS/WED) has been previously reported. \"Emplotted Narratives\" and Structured \"Behavioral Observations\" Supporting the Diagnosis of Willis-Ekbom Disease/Restless Legs Syndrome in Children with Neurodevelopmental Conditions. BACKGROUND: Willis-Ekbom disease/restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia (ICI) but is under-recognized in children/adolescents with neurodevelopmental conditions (NDCs), as many patients do not have the ability to express the underlying \"urge-to-move\". Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterised by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement. "
    },
    {
      "exact_answer": [
        [
          "Enhancer of transcription"
        ],
        [
          "Sea"
        ],
        [
          "Entire cell"
        ],
        [
          "Databases"
        ],
        [
          "ethylene diurea"
        ],
        [
          "Identified"
        ],
        [
          "Internet"
        ],
        [
          "Published Database"
        ],
        [
          "Providing (action)"
        ],
        [
          "Mus"
        ],
        [
          "Body tissue"
        ],
        [
          "Disease"
        ],
        [
          "user - individual"
        ],
        [
          "cell type"
        ],
        [
          "Search - action"
        ],
        [
          "Processing Mode - Archive"
        ],
        [
          "Numerous"
        ],
        [
          "accessibility"
        ],
        [
          "HTTP"
        ],
        [
          "Species"
        ],
        [
          "Scientific Equipment"
        ],
        [
          "Data"
        ],
        [
          "Interaction"
        ],
        [
          "Sense of identity (observable entity)"
        ],
        [
          "Genome - anatomical entity"
        ],
        [
          "Genes"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Social Role"
        ],
        [
          "Design"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Hyperlink"
        ],
        [
          "Entrez"
        ],
        [
          "Resources"
        ],
        [
          "Galaxies"
        ],
        [
          "University of California at Santa Cruz"
        ],
        [
          "anthropological customs"
        ],
        [
          "Clustered Regularly Interspaced Short Palindromic Repeats"
        ],
        [
          "Assortment"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Send (transmission)"
        ],
        [
          "Destination site"
        ],
        [
          "server (role)"
        ],
        [
          "Gene Identifier"
        ],
        [
          "Export"
        ],
        [
          "Caenorhabditis elegans"
        ],
        [
          "Friendly"
        ],
        [
          "Helping Behavior"
        ],
        [
          "Extrinsic"
        ],
        [
          "Format"
        ],
        [
          "Drosophila melanogaster"
        ],
        [
          "Track (course)"
        ],
        [
          "DNA Microarray Chip"
        ],
        [
          "Instance"
        ],
        [
          "Histocompatibility Testing"
        ],
        [
          "Geographic Locations"
        ],
        [
          "Act Mood - Goal"
        ],
        [
          "Overlap"
        ],
        [
          "List"
        ],
        [
          "Universal Protein Resource"
        ],
        [
          "Conservation"
        ],
        [
          "Details"
        ],
        [
          "DNA Methylation"
        ],
        [
          "Processed"
        ],
        [
          "Definition"
        ],
        [
          "Responsive"
        ],
        [
          "Easy"
        ],
        [
          "Professional Organization or Group"
        ],
        [
          "Identity"
        ],
        [
          "Downstream"
        ],
        [
          "Interface Device Component"
        ],
        [
          "Focal"
        ],
        [
          "Options"
        ],
        [
          "Depth"
        ],
        [
          "Single Nucleotide Polymorphism"
        ],
        [
          "Scientific Study"
        ],
        [
          "biology (field)"
        ],
        [
          "Support, device"
        ],
        [
          "Comprehensive"
        ],
        [
          "Data Extraction"
        ],
        [
          "Transcriptional Regulation"
        ],
        [
          "Location"
        ],
        [
          "Biological Evolution"
        ],
        [
          "Primary operation"
        ],
        [
          "Base Sequence"
        ],
        [
          "Relationships"
        ],
        [
          "Specificity"
        ],
        [
          "Visual"
        ],
        [
          "Community"
        ],
        [
          "Genome"
        ],
        [
          "Efficient"
        ],
        [
          "transcription factor binding"
        ],
        [
          "Release - action (qualifier value)"
        ],
        [
          "Additional"
        ],
        [
          "Gene Expression Regulation"
        ],
        [
          "Site"
        ],
        [
          "Genetic"
        ],
        [
          "Types of diseases"
        ],
        [
          "Genetic Research"
        ],
        [
          "Greater"
        ],
        [
          "Current (present time)"
        ]
      ],
      "id": "587d2700fe8a08052f000001",
      "ideal_answer": "To facilitate data extraction, SEA supports multiple search options, including species, genome location, gene name, cell type/tissue and super-enhancer name. The response provides detailed (epi)genetic information, incorporating cell type specificity, nearby genes, transcriptional factor binding sites, CRISPR/Cas9 target sites, evolutionary conservation, SNPs, H3K27ac, DNA methylation, gene expression and TF ChIP-seq data. We developed dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease. SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene expression. The current release of SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases, including human (75 439, three of which were experimentally identified), mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans (904). Moreover, analytical tools and a genome browser were developed for users to explore super-enhancers and their roles in defining cell identity and disease processes in depth. "
    },
    {
      "exact_answer": "yes",
      "id": "58a6bce660087bc10a000029",
      "ideal_answer": "Inherited BRCA gene mutations convey a high risk for breast and ovarian cancer, but current guidelines limit BRCA mutation testing to women with early-onset cancer and relatives of mutation-positive cases. Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families. Little is known about how women with hereditary breast and/or ovarian cancer who test positive for a BRCA gene manage the impact of a positive test result on their everyday lives and in the longer term. The assessment of BRCA1 and BRCA2 coding sequences to identify pathogenic mutations associated with inherited breast/ovarian cancer syndrome has provided a method to identify high-risk individuals, allowing them to seek preventative treatments and strategies. p \u003d 2.7 × 10(-3)) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95%CI: 1.03-1.21,. BRCA1 and BRCA2 are two major genes associated with familial breast and ovarian cancer susceptibility. Women who carry a BRCA1 or BRCA2 gene mutation face a risk of developing breast or ovarian cancer at an earlier age than women without such a mutation. "
    },
    {
      "exact_answer": "yes",
      "id": "58a341eb60087bc10a000018",
      "ideal_answer": "Statin use has been associated with increased risk of developing type 2 diabetes (T2DM), and with impaired glycemic control in T2DM patients. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events. "
    },
    {
      "exact_answer": [
        [
          "PLK1 protein, human"
        ],
        [
          "CDC2 Protein Kinase"
        ],
        [
          "BORA gene"
        ],
        [
          "Phosphotransferases"
        ],
        [
          "Aurora Kinase A"
        ],
        [
          "PLK1 gene"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Protein phosphorylation"
        ],
        [
          "Glycogen Synthase Kinase 3"
        ],
        [
          "Contribution"
        ],
        [
          "Activation action"
        ],
        [
          "AGXT gene"
        ],
        [
          "Site"
        ],
        [
          "assay qualifier"
        ],
        [
          "Belarus"
        ],
        [
          "Assortment"
        ],
        [
          "Phosphopeptides"
        ],
        [
          "Multiply - dosing instruction fragment"
        ],
        [
          "suggestion"
        ],
        [
          "Catabolism"
        ],
        [
          "Master"
        ],
        [
          "Generic Role"
        ],
        [
          "Mitotic"
        ],
        [
          "Promotion (action)"
        ],
        [
          "Processed"
        ],
        [
          "Cell division"
        ],
        [
          "Consensus"
        ],
        [
          "Mapping (action)"
        ],
        [
          "Block (unit of measure)"
        ],
        [
          "Liquid Chromatography Mass Spectrometry"
        ],
        [
          "Phosphorylation"
        ],
        [
          "Phosphorylation Site"
        ],
        [
          "Characterization"
        ],
        [
          "Finding"
        ],
        [
          "Cell Cycle"
        ],
        [
          "cyclin-dependent protein kinase activity"
        ],
        [
          "In Vivo"
        ],
        [
          "Mechanism (attribute)"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Potential"
        ]
      ],
      "id": "58a80bc838c171fb5b000001",
      "ideal_answer": "During cell division Bora becomes multiply phosphorylated by a variety of cell cycle kinases, including Aurora A and Plk1, albeit at distinctive sites. Likewise, we find that phosphorylation of Bora by Cdk1 promotes phosphorylation of human Plk1 by Aurora A suggesting that this mechanism is conserved in humans. we show that the master mitotic kinase Cdk1 contributes to Plk1 activation through SPAT-1/Bora phosphorylation. the potential role of Bora phosphorylation by Cdk1 in this process. Here, we used the LC-MS/MS phosphopeptide mapping assay to identify 13 in vivo hBora phosphorylation sites and characterized that GSK3β can interact with hBora and phosphorylate hBora at Ser274 and Ser278. phosphorylation of Bora on the Cdk consensus site T52 blocks Bora degradation. "
    },
    {
      "exact_answer": [
        [
          "rucaparib"
        ],
        [
          "Poly(ADP-ribose) Polymerases"
        ],
        [
          "veliparib"
        ],
        [
          "Poly(ADP-ribose) polymerase inhibitor"
        ],
        [
          "Olaparib"
        ]
      ],
      "id": "5880be1dc872c95565000007",
      "ideal_answer": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles. Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer. There are a number of other PARP inhibitors in late phase clinical development in ovarian cancer including rucaparib, niraparib, veliparib, and talazoparib. Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status. METHODS: Here we examine the response to niraparib, a potent PARP-1/PARP-2 inhibitor currently under clinical evaluation, in MSI versus microsatellite stable (MSS) CRC cell lines in vitro and in vivo. We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability. "
    },
    {
      "id": "587e3f4e2420191125000003",
      "ideal_answer": "regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. regioneR is an R package that implements a permutation test framework specifically designed to work with genomic regions. In addition to the predefined randomization and evaluation strategies, regioneR is fully customizable allowing the use of custom strategies to adapt it to specific questions. Finally, it also implements a novel function to evaluate the local specificity of the detected association. "
    },
    {
      "id": "589c389278275d0c4a00003e",
      "ideal_answer": "Although levodopa is considered the gold standard for Parkinson\u0027s disease therapy, prolonged use of this drug can result in motor complications such as a \u0027wearing-off\u0027 phenomenon. Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia. One of the first complications observed with levodopa therapy is wearing-off, which can emerge within 1-3 years of initiation of levodopa treatment. This outcome is seen in a significant number of patients with Parkinson\u0027s disease taking levodopa and, in some cases, is observed only a few hours after intake of the last dose of levodopa. We report here on a patient with Parkinson\u0027s disease who was taking levodopa and developed both shortness of breath and hyperventilation during wearing-off periods. The wearing-off phenomenon in patients with Parkinson\u0027s disease (PD) is a complication of prolonged levodopa usage. His shortness of breath was determined to be a wearing-off phenomenon and his condition improved with the addition of a catechol-O-methyltransferase inhibitor (entacapone). Patients with wearing-off tended to receive higher L-dopa dosage and endure longer duration of L-dopa treatment. It is unlike the \"wearing-off\" phenomenon that occurs when dopaminergic drug levels decline and responds to dopaminergic rescue drugs. "
    },
    {
      "id": "589c8ef878275d0c4a000042",
      "ideal_answer": "two biomedical named entity recognition (NER) comparative evaluations that have been held to date, namely BioCreative and Coling. The BioCreative II.5 community challenge addressed these tasks in a competition-style assessment to evaluate and compare different methodologies, to make aware of the increasing accuracy of automated methods, and to guide future implementations. In task 1A of the BioCreAtIvE evaluation, systems had to be devised that recognize words and phrases forming gene or protein names in natural language sentences. BioCreAtIvE, a competition for automated gene/protein name recognition. In this paper, we present our approaches for protein-named entity recognition,. "
    },
    {
      "exact_answer": [
        [
          "Nocodazole"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Induce (action)"
        ],
        [
          "Internal-External Locus of Control Scale"
        ],
        [
          "spindle assembly checkpoint"
        ]
      ],
      "id": "58a8903b38c171fb5b000006",
      "ideal_answer": "the treatment of CD4+T-cells with nocodazole, which disrupts the microtubular network,. Cells can also be enriched in mitosis using nocodazole. escape of metaphase I arrest induced by nocodazole treatment. antimitotic SAC-inducing agents (i.e., nocodazole. nocodazole-triggered mitotic arrest. spindle assembly checkpoint (SAC). "
    },
    {
      "exact_answer": [
        [
          "LCS1 gene"
        ],
        [
          "Cholestasis-edema syndrome, Norwegian type"
        ],
        [
          "Cholestasis"
        ],
        [
          "Intermittent"
        ],
        [
          "Chronic acquired lymphedema"
        ],
        [
          "Characterization"
        ],
        [
          "Cholestasis in newborn"
        ],
        [
          "Intrahepatic Cholestasis"
        ],
        [
          "intrahepatic"
        ],
        [
          "Neonatal Clinical Nurse Specialist"
        ],
        [
          "Progressive intrahepatic cholestasis (disorder)"
        ],
        [
          "Call (Instruction)"
        ],
        [
          "Background"
        ],
        [
          "Congenital obstruction of bile duct"
        ],
        [
          "Frequent"
        ],
        [
          "Patient need for (contextual qualifier)"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Age"
        ],
        [
          "Patients"
        ],
        [
          "Associated with"
        ],
        [
          "Integer +2"
        ],
        [
          "Lymphedema of the extremities"
        ],
        [
          "Lymphedema"
        ],
        [
          "Body Site Modifier - Lower"
        ],
        [
          "Extrinsic"
        ],
        [
          "Outpatients"
        ],
        [
          "Autosomal recessive inheritance"
        ],
        [
          "Obese build"
        ],
        [
          "Lower Extremity"
        ],
        [
          "Exhibits as Topic"
        ],
        [
          "Sporadic"
        ],
        [
          "Episode of"
        ],
        [
          "Legal Adult"
        ],
        [
          "Room of building - Study"
        ],
        [
          "Edema"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Entire lower limb"
        ],
        [
          "Qualitative form"
        ],
        [
          "Childhood"
        ],
        [
          "Diet education"
        ],
        [
          "Diet"
        ],
        [
          "Unknown (origin) (qualifier value)"
        ],
        [
          "Rare"
        ],
        [
          "Rare Diseases"
        ],
        [
          "Aim (idea)"
        ],
        [
          "Syndrome"
        ],
        [
          "Reduced"
        ],
        [
          "Examined"
        ],
        [
          "Thinking, function"
        ],
        [
          "Disease"
        ]
      ],
      "id": "5895f9cf78275d0c4a000002",
      "ideal_answer": "BACKGROUND: Lymphedema-cholestasis syndrome (LCS; Aagenaes syndrome) is a rare autosomal recessive disorder, characterized by 1) neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age, and 2) severe chronic lymphedema, mainly lower limb. Aagenaes syndrome, also called lymphoedema cholestasis syndrome 1 (LSC1), is characterized by neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age and severe chronic lymphoedema, mainly affecting the lower extremities. BACKGROUND \u0026 AIMS: Patients with lymphoedema cholestasis syndrome 1/Aagenaes Syndrome need a fat reduced diet when cholestatic. Do patients with lymphoedema cholestasis syndrome 1/Aagenaes syndrome need dietary counselling outside cholestatic episodes?. The patients exhibited lymphedema and sporadic cholestasis. The disease was thought to be caused by a congenital cholestatic syndrome associated with intermittent oedema in childhood, resembling the rare Aagenaes syndrome. Aagenaes syndrome, also called Lymphedema Cholestasis Syndrome (LSC 1), is a form of idiopathic familial intrahepatic cholestasis associated with lymphedema of the lower extremities. In this study, 17 out of 20 Norweigian adult patients with lymphedema cholestasis syndrome 1 (LCS1)/Aagenaes syndrome were examined. "
    },
    {
      "exact_answer": [
        [
          "Locus"
        ],
        [
          "Enrich"
        ],
        [
          "Contig"
        ],
        [
          "Inference"
        ],
        [
          "Theses"
        ]
      ],
      "id": "587e07023ec846c24f000001",
      "ideal_answer": "Prior to downstream inference, data from these types of targeted enrichment studies must undergo preprocessing to assemble contigs from sequence data; identify targeted, enriched loci from the off-target background data; align enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE is an efficient and easy-to-install software package that accomplishes these tasks across hundreds of taxa and thousands of enriched loci. PHYLUCE is a software package for the analysis of conserved genomic loci. "
    },
    {
      "exact_answer": [
        [
          "Synucleins"
        ],
        [
          "Lewy Bodies"
        ],
        [
          "SNCA gene"
        ],
        [
          "Parkinson\u0027s Disease Pathway"
        ],
        [
          "Protein Component"
        ]
      ],
      "id": "58a2e5f760087bc10a000007",
      "ideal_answer": "Aggregation of α-synuclein (αSyn), the primary protein component in Lewy body inclusions of patients with Parkinson\u0027s disease, arises when the normally soluble intrinsically disordered protein converts to amyloid fibrils. Fibrillar α-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson\u0027s disease. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson\u0027s disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). The protein alpha-synuclein (AS) is the primary fibrillar component of Lewy bodies, the pathological hallmark of Parkinson\u0027s disease. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission. Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson\u0027s Disease. "
    },
    {
      "exact_answer": "yes",
      "id": "58a341a660087bc10a000017",
      "ideal_answer": "Animals treated with trace elements recovered. It appears that intestinal microbiota dysbiosis and trace element deficiency could explain the extensive emergence of chronic Botulism. The patient was treated with human botulism immune globulin and had rapid recovery in weakness. A stool sample from the patient was positive for Type A Clostridium botulinum toxin eventually confirming the diagnosis of infant botulism. The botulism immunoglobulin was administered, and a diagnosis was confirmed with positive botulinum toxin in the stool samples. Full recovery was made by the infant. "
    },
    {
      "exact_answer": "yes",
      "id": "58aa0a62396a458e50000007",
      "ideal_answer": "Together with detyrosination, glutamylation and other modifications, tubulin acetylation may form a unique \u0027language\u0027 to regulate microtubule structure and function. Enzymes of the tubulin tyrosine ligase-like (TTLL) family posttranslationally modify and thereby mark microtubules by glutamylation, generating specific recognition sites for microtubule-interacting proteins. Glutamylation, the most prevalent tubulin posttranslational modification, marks stable microtubules and regulates recruitment and activity of microtubule- interacting proteins. PTMs of the cytoskeleton, including phosphorylation, glycosylation, ubiquitination, detyrosination/tyrosination, (poly)glutamylation and (poly)glycylation, acetylation, sumoylation, and palmitoylation, will be addressed in this chapter. The tubulin posttranslational modifications: acetylation, detyrosination, polyglutamylation, and polyglycylation play important roles in microtubule functions. In most eukaryotic cells, tubulin is subjected to posttranslational glutamylation, a conserved modification of unclear function. "
    },
    {
      "exact_answer": [
        [
          "teriflunomide"
        ],
        [
          "Magnesium Cation"
        ],
        [
          "fingolimod"
        ],
        [
          "Tower"
        ],
        [
          "Adrenal Cortex Hormones"
        ]
      ],
      "id": "589a246078275d0c4a00002a",
      "ideal_answer": "OBJECTIVE: To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). Using data from pivotal studies of DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451), fingolimod (FREEDOMS, NCT00289978; FREEDOMS II, NCT00355134), and teriflunomide (TEMSO, NCT00134563; TOWER, NCT00751881), we calculated NNTs to prevent any relapse, more severe relapses (such as those leading to hospitalization or requiring intravenous corticosteroids), and disability worsening. CONCLUSIONS: In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. METHODS: In September 2012, the US Food and Drug Administration granted approval for the use of teriflunomide, 14 mg and 7 mg once daily, to treat RMS on the basis of the results of a Phase II study and the Phase III TEMSO (Teriflunomide Multiple Sclerosis Oral) trial. Teriflunomide treatment was also associated with significant efficacy on MRI measures of disease activity in TEMSO; both doses significantly reduced total lesion volume and number of gadolinium-enhancing T1 lesions. "
    },
    {
      "exact_answer": "yes",
      "id": "587f5d6492a5b8ad44000003",
      "ideal_answer": "Exon Skipping Is Correlated with Exon Circularization. We find that circularization of exons is widespread and correlates with exon skipping, a feature that adds considerably to the regulatory complexity of the human transcriptome. "
    },
    {
      "exact_answer": [
        [
          "YWHAE wt Allele"
        ],
        [
          "Fluorescent in Situ Hybridization"
        ],
        [
          "Dysmyelopoietic Syndromes"
        ],
        [
          "Detection"
        ],
        [
          "Chromosome 7q"
        ],
        [
          "Chromosome 8, trisomy"
        ],
        [
          "Fish (food)"
        ],
        [
          "Case unit dose"
        ],
        [
          "Fishes"
        ],
        [
          "teratologic"
        ],
        [
          "Interphase"
        ],
        [
          "Chromosome 7, monosomy"
        ],
        [
          "Shprintzen syndrome"
        ],
        [
          "chromosome 5q"
        ],
        [
          "20q"
        ],
        [
          "N not otherwise specified Antibody"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Patients"
        ],
        [
          "Preleukemia"
        ],
        [
          "Preposition For"
        ],
        [
          "Chromosome Deletion"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "classical example"
        ],
        [
          "Detected (finding)"
        ],
        [
          "Miller Dieker syndrome"
        ],
        [
          "Clone Cells"
        ],
        [
          "Conclude Resin"
        ],
        [
          "Aberrant"
        ],
        [
          "Angelman Syndrome"
        ],
        [
          "22q11.2"
        ],
        [
          "shared attribute"
        ],
        [
          "Leukemia, Myelocytic, Acute"
        ],
        [
          "Deletion (action)"
        ],
        [
          "Probes"
        ],
        [
          "Karyotype determination procedure"
        ],
        [
          "Isochromosomes"
        ],
        [
          "Case (situation)"
        ],
        [
          "Positive Finding"
        ],
        [
          "Shwachman syndrome"
        ],
        [
          "TET2 gene"
        ],
        [
          "Contribution"
        ],
        [
          "Cytogenetics"
        ],
        [
          "Frequent"
        ],
        [
          "SNP Info"
        ],
        [
          "Laboratory Order Panels"
        ],
        [
          "Chromosome Aberrations"
        ],
        [
          "Experimental Result"
        ],
        [
          "Geographic Locations"
        ],
        [
          "Providing (action)"
        ],
        [
          "coenzyme Q10"
        ],
        [
          "Copy Number Polymorphism"
        ],
        [
          "Specimen"
        ],
        [
          "Abnormal Karyotype"
        ],
        [
          "Confidentiality - sensitive"
        ],
        [
          "Cytogenetic Analysis"
        ],
        [
          "Cosmids"
        ],
        [
          "MLPA"
        ],
        [
          "Involvement with"
        ],
        [
          "telomere"
        ],
        [
          "Diagnosis"
        ],
        [
          "Chromosomes"
        ],
        [
          "assay qualifier"
        ],
        [
          "Congenital chromosomal disease"
        ],
        [
          "Histidine"
        ],
        [
          "Williams Syndrome"
        ],
        [
          "Unbalanced Translocation"
        ],
        [
          "Method of detection"
        ],
        [
          "Belarus"
        ],
        [
          "Confirmed by"
        ],
        [
          "Phenotype determination"
        ],
        [
          "Techniques"
        ],
        [
          "DNA, Satellite"
        ],
        [
          "Syndrome"
        ],
        [
          "Musculoskeletal torsion, function"
        ],
        [
          "Sex Chromosome Aberrations"
        ],
        [
          "Craniosynostosis"
        ],
        [
          "Exons"
        ],
        [
          "Integer +5"
        ],
        [
          "Spectral Karyotyping"
        ],
        [
          "Characterization"
        ],
        [
          "Evaluation"
        ],
        [
          "Gene Deletion Abnormality"
        ],
        [
          "Abnormality"
        ],
        [
          "Singular"
        ],
        [
          "Bromodeoxyuridine"
        ],
        [
          "Arising in"
        ],
        [
          "Mice, Inbred CBA"
        ],
        [
          "Categories"
        ],
        [
          "Science of Etiology"
        ],
        [
          "DNA Probes"
        ],
        [
          "Therapy-related myelodysplastic syndrome"
        ],
        [
          "Chromosomes, Human, Pair 7"
        ],
        [
          "Chromosomes, Human, Pair 5"
        ],
        [
          "error"
        ],
        [
          "Array"
        ],
        [
          "Mitotic Metaphase"
        ],
        [
          "Negation"
        ],
        [
          "Complex Karyotype"
        ],
        [
          "Percent normal"
        ],
        [
          "probe gene fragment"
        ]
      ],
      "id": "58932cd87d9090f353000001",
      "ideal_answer": "Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance. Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. As chromosomal instability may contribute to leukemogenesis in patients with congenital bone marrow failure (CBMF) disorders, it was the aim of this study to characterize chromosomally aberrant clones that arise during the clinical course of disease by means of R-banding and fluorescence in situ hybridization (FISH) analyses. A 15-year-old male with myelodysplastic syndrome (MDS) characterized by monosomy 7 was cytogenetically evaluated by metaphase karyotyping and fluorescence in situ hybridization (FISH) of interphase cells at six different points during the course of his disease. Here we assess this capability by applying array CGH to the analysis of copy number alterations in 44 patients with a phenotype of the 22q11.2. Fluorescence in situ hybridization (FISH) with a chromosome 7 specific alpha satellite DNA probe was used to detect monosomy 7 in interphase and metaphase cells obtained from patients with myelodysplastic syndrome (MDS) and acute nonlymphocytic leukemia (ANLL). "
    },
    {
      "exact_answer": [
        [
          "Oral Poliovirus Vaccine"
        ],
        [
          "Poliovirus Vaccine, Inactivated"
        ],
        [
          "United States"
        ],
        [
          "Jonas"
        ],
        [
          "Belarus"
        ]
      ],
      "id": "58a1c0f178275d0c4a000056",
      "ideal_answer": "the use of an oral polio vaccine (OPV) during a vaccination campaign launched by the Wistar Institute, Philadelphia, PA, USA, in the Belgian Congo in 1958 and 1959. Inactivated poliovirus vaccine (IPV), developed in the USA by Jonas Salk in the early 1950s, was field tested in 1954,. "
    },
    {
      "exact_answer": "yes",
      "id": "58a8962338c171fb5b000007",
      "ideal_answer": "Synapsin is an evolutionarily conserved presynaptic phosphoprotein. Synapsins as a family of presynaptic terminal phosphoprotein participates in neuronal development. Synapsin II is a member of the neuronal phosphoprotein family. The neuronal phosphoprotein synapsin III. Synapsin III (SynIII) is a phosphoprotein. phosphoprotein synapsin. "
    },
    {
      "exact_answer": [
        [
          "Ataxia"
        ],
        [
          "Sensorineural Hearing Loss (disorder)"
        ],
        [
          "Epilepsy"
        ],
        [
          "KCNJ10 gene"
        ],
        [
          "SeSAME syndrome"
        ],
        [
          "Cardinalis cardinalis"
        ],
        [
          "Oligonucleotides, Antisense"
        ],
        [
          "Potassium Channel"
        ],
        [
          "East"
        ],
        [
          "Renal tubular defect"
        ],
        [
          "Mutation"
        ],
        [
          "Symptoms"
        ],
        [
          "TRICHOHEPATOENTERIC SYNDROME"
        ],
        [
          "Acronyms"
        ],
        [
          "Morpholinos"
        ],
        [
          "Renal salt wasting"
        ],
        [
          "Logical Condition"
        ],
        [
          "disabling disease"
        ],
        [
          "Zebrafish"
        ],
        [
          "Infancy"
        ],
        [
          "Generations"
        ],
        [
          "Consistency"
        ],
        [
          "Encode (action)"
        ],
        [
          "Seizures"
        ],
        [
          "Validation"
        ],
        [
          "Mental blocking"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Genetic Translation Process"
        ],
        [
          "Feature"
        ],
        [
          "Characterization"
        ],
        [
          "Organ"
        ],
        [
          "Contain (action)"
        ],
        [
          "Numerous"
        ],
        [
          "apparent"
        ],
        [
          "Injection procedure"
        ],
        [
          "Aim (idea)"
        ],
        [
          "Syndrome"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Identified"
        ],
        [
          "Report (document)"
        ],
        [
          "Model"
        ],
        [
          "Associated with"
        ]
      ],
      "id": "589a246378275d0c4a00002c",
      "ideal_answer": "This condition is characterized by 4 cardinal features; Epilepsy, Ataxia, Sensorineural deafness, and (a renal salt-wasting) Tubulopathy, hence the acronym EAST syndrome. Recessive mutations in KCNJ10, which encodes an inwardly rectifying potassium channel, were recently identified as the cause of EAST syndrome, a severe and disabling multi-organ disorder consisting of epilepsy, ataxia, sensorineural deafness and tubulopathy that becomes clinically apparent with seizures in infancy. AIM: Recently, we reported a previously unrecognized symptom constellation comprising epilepsy, ataxia, sensorineural deafness, and tubulopathy (EAST syndrome) associated with recessive mutations in the KCNJ10 gene. We next injected splice- and translation-blocking kcnj10 antisense morpholino oligonucleotides and reproduced the cardinal symptoms of EAST syndrome - ataxia, epilepsy and renal tubular defects. Generation and validation of a zebrafish model of EAST (epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome. "
    },
    {
      "id": "5889f0ed3b87a8a73800000c",
      "ideal_answer": "Microcephaly gene links trithorax and REST/NRSF to control neural stem cell proliferation and differentiation. RNA-interference and postmortem human studies show that ZNF335 is essential for neural progenitor self-renewal, neurogenesis, and neuronal differentiation. Znf335 null mice are embryonically lethal, and conditional knockout leads to severely reduced cortical size. "
    },
    {
      "id": "589afa6978275d0c4a000039",
      "ideal_answer": "Exploiting chimeric human antibodies to characterize a protective epitope of Neisseria adhesin A, one of the Bexsero vaccine components. Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. A new vaccine (the 4CMenB 4-component protein vaccine [Bexsero], which includes PorA, factor H-binding protein [fHbp], neisserial heparin-binding antigen [NHBA], and Neisseria adhesin A [NadA]) against serogroup B meningococci has recently been approved for use in people older than age 2 months in Europe, Australia, and Canada. To broaden the scope of its protection, the multicomponent vaccine (4CMenB) incorporates a PorA-containing outer membrane vesicle (OMV) alongside relatively conserved recombinant protein components, including factor H-binding protein (fHbp), Neisseria adhesin A (NadA), and neisserial heparin-binding antigen (NHBA). Serum bactericidal activity using human complement (hSBA) was measured against three reference strains 44/76-SL, 5/99 and NZ98/254, selected to express one of the vaccine antigens; Neisseria adhesin A (NadA), factor H binding protein (fHbp) and porin A (PorA) containing outer membrane vesicle (OMV), respectively. "
    },
    {
      "exact_answer": "yes",
      "id": "58a0d87a78275d0c4a000053",
      "ideal_answer": "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome,. Thalidomide could relieve clinical symptoms and intestinal mucosal lesions effectively in children with refractory inflammatory bowel disease (IBD) from the pre-clinical study. In this retrospective study, pharmacy claims were analyzed for those patients with a diagnosis of MM who received thalidomide,. "
    },
    {
      "exact_answer": [
        [
          "Oxytocin"
        ],
        [
          "Pyschological Bonding"
        ],
        [
          "Hormones"
        ],
        [
          "Psyche structure"
        ],
        [
          "Posterior Pituitary Hormones"
        ]
      ],
      "id": "58aa0c6f396a458e50000008",
      "ideal_answer": "The neurohypophysial hormone oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related responses. Neuropeptide hormone oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health. Oxytocin is known as the \u0027love hormone\u0027 due its role in promoting mother-child and pair bonding. The oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian lineages. oxytocin, a hormone involved in parent-offspring bonding. "
    },
    {
      "id": "5895fc7e78275d0c4a000003",
      "ideal_answer": "We report two siblings with congenital generalized hypertrichosis and distinctive facial appearance consistent with the dysmorphic facial features described in Ambras syndrome. In 1993, Baumister et al. described congenital hypertrichosis lanuginose or Ambras syndrome: a distinct form of congenital hypertrichosis characterized by excessive hair growth over the body and face associated with facial and occasional dental anomalies. Ambras syndrome is a rare and special form of congenital hypertrichosis, characterized by dysmorphic facial features and familial pattern of inheritance. Ambras syndrome (AS) is a rare form of congenital hypertrichosis with excessive hair on the shoulders, face and ears. Ambras syndrome (AMS) is a unique form of universal congenital hypertrichosis. In patients with this syndrome, the whole body is covered with fine long hair, except for areas where normally no hair grows. There is accompanying facial dysmorphism and teeth abnormalities, including retarded first and second dentition and absence of teeth. "
    },
    {
      "id": "587e42032420191125000004",
      "ideal_answer": "MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes. Here we report the discovery of a new family of DUBs, which we have named MINDY (motif interacting with Ub-containing novel DUB family). Found in all eukaryotes, MINDY-family DUBs are highly selective at cleaving K48-linked polyUb, a signal that targets proteins for degradation. We identify the catalytic activity to be encoded within a previously unannotated domain, the crystal structure of which reveals a distinct protein fold with no homology to any of the known DUBs. The crystal structure of MINDY-1 (also known as FAM63A) in complex with propargylated Ub reveals conformational changes that realign the active site for catalysis. Collectively, our results reveal a new family of DUBs that may have specialized roles in regulating proteostasis. MINDY-1 prefers cleaving long polyUb chains and works by trimming chains from the distal end. "
    },
    {
      "exact_answer": [
        [
          "Catecholamines"
        ],
        [
          "Mixed Function Oxygenases"
        ],
        [
          "Dopamine"
        ],
        [
          "RNA, Messenger"
        ],
        [
          "enzymology"
        ],
        [
          "TH gene"
        ],
        [
          "PNMT gene"
        ],
        [
          "Corticosterone"
        ],
        [
          "salicylhydroxamic acid"
        ],
        [
          "Enzymes"
        ],
        [
          "Pheochromocytoma"
        ],
        [
          "Rattus norvegicus"
        ],
        [
          "Adrenal Medulla"
        ],
        [
          "ethanolamine"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ],
        [
          "Aromatic-L-Amino-Acid Decarboxylases"
        ],
        [
          "Methyltransferase"
        ],
        [
          "operate"
        ],
        [
          "DDC gene"
        ],
        [
          "DBH gene"
        ],
        [
          "Adrenal Glands"
        ],
        [
          "control substance"
        ],
        [
          "Right ventricular structure"
        ],
        [
          "Triad Acrylic Resin"
        ],
        [
          "Housing"
        ],
        [
          "Changing"
        ],
        [
          "Coding"
        ],
        [
          "Obesity"
        ],
        [
          "Negation"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "P Blood group antibodies"
        ],
        [
          "Examined"
        ],
        [
          "Expression procedure"
        ],
        [
          "Gene Expression"
        ],
        [
          "Dopamine-beta-monooxygenase"
        ],
        [
          "Percentile"
        ],
        [
          "catecholamine secretion"
        ],
        [
          "Family suidae"
        ],
        [
          "NOAC protocol"
        ],
        [
          "Reduced"
        ],
        [
          "CFH gene"
        ],
        [
          "Anabolism"
        ],
        [
          "Integer +2"
        ],
        [
          "Unmarried"
        ],
        [
          "Entire medulla oblongata"
        ],
        [
          "Systole"
        ],
        [
          "Body Site Modifier - Lower"
        ],
        [
          "Weighing patient"
        ],
        [
          "Comprehension"
        ],
        [
          "Spinal cage"
        ],
        [
          "Abnormally high"
        ],
        [
          "Treadmill (physical activity)"
        ],
        [
          "Pacing induced cardiomyopathy"
        ],
        [
          "Pacing up and down"
        ],
        [
          "P prime"
        ],
        [
          "K Prime"
        ],
        [
          "Catecholamine level finding"
        ],
        [
          "catecholamine biosynthetic process"
        ],
        [
          "Specimen Source Codes - tumor"
        ],
        [
          "Tachycardia"
        ],
        [
          "Investigates"
        ],
        [
          "Morphologically altered structure"
        ],
        [
          "Running (physical activity)"
        ],
        [
          "Tachycardia-induced cardiomyopathy"
        ],
        [
          "Action Code - No change"
        ],
        [
          "User Group"
        ],
        [
          "Messenger (Occupation)"
        ],
        [
          "Legal Adult"
        ],
        [
          "phenyl"
        ],
        [
          "Bed Status - Isolated"
        ],
        [
          "cAMP response element binding"
        ],
        [
          "Mouse Adrenal Gland"
        ],
        [
          "Rat Adrenal Gland"
        ],
        [
          "Immunohistochemistry"
        ],
        [
          "Protein Overexpression"
        ],
        [
          "Scientific Study"
        ],
        [
          "Ischemic"
        ],
        [
          "Percent normal"
        ],
        [
          "Exercise Pain Management"
        ],
        [
          "Exercise"
        ],
        [
          "Mental concentration"
        ],
        [
          "Basal"
        ],
        [
          "Relationships"
        ],
        [
          "Finding of enzyme level"
        ],
        [
          "Protein level - finding"
        ],
        [
          "With intensity"
        ],
        [
          "findings aspects"
        ],
        [
          "week"
        ],
        [
          "Differential quality"
        ],
        [
          "Concentration measurement"
        ],
        [
          "First Step"
        ],
        [
          "Daily"
        ],
        [
          "Social group"
        ],
        [
          "Social"
        ],
        [
          "Absence (morphologic abnormality)"
        ],
        [
          "Stimulation (motivation)"
        ],
        [
          "Male Gender, Self Report"
        ],
        [
          "Stress"
        ],
        [
          "Individual"
        ],
        [
          "Animals"
        ]
      ],
      "id": "589c215778275d0c4a00003c",
      "ideal_answer": "We analyzed the mRNA levels of catecholamine-synthesizing enzymes: tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AAAD), dopamine-β-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT) in adrenal glands of 18 pigs with chronic systolic non-ischaemic HF (tachycardia-induced cardiomyopathy due to right ventricle pacing) and 6 sham-operated controls. This study aimed to investigate physical exercise-related changes in gene expression of catecholamine biosynthetic enzymes (tyrosine hydroxylase, dopamine-ß-hydroxylase and phenylethanolamine N-methyltransferase) and cyclic adenosine monophosphate response element-binding (CREB) in the adrenal medulla, concentrations of catecholamines and corticosterone (CORT) in the plasma and the weight of adrenal glands of chronically psychosocially stressed adult rats exposed daily to 20 min treadmill running for 12 weeks. The present studies examined the effect of 70 days of triad (3 rats per large cage) and individual housing of male rats on adrenal mRNA levels of tyrosine hydroxylase (TH), dopamine-beta-hydroxylase (DBH) and phenylethanolamine-N-methyltransferase (PNMT) and on TH protein levels. As a first step toward understanding the molecular mechanisms by which catecholamine synthesis is controlled in the tumor, we measured the levels of mRNA coding for the catecholamine synthesizing enzyme, tyrosine hydroxylase (TH) and catecholamines in 6 pheochromocytomas and 2 normal adrenal glands. "
    },
    {
      "id": "58a3160d60087bc10a00000a",
      "ideal_answer": "Fatal familial insomnia is a rare disease caused by a D178N mutation in combination with methionine (Met) at codon 129 in the mutated allele of PRNP (D178N-129M haplotype). Point mutations or the insertions of one or more copies of a 24 bp repeat are associated with familial human prion diseases including familial Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia. FFI is manifested by sleep disturbances with insomnia, autonomic disorders and spontaneous and evoked myoclonus, among other symptoms. Familial fatal insomnia (FFI) is fatal disorder characterized by damage to select thalamic nuclei, together with progressive insomnia and dysautonomia. "
    },
    {
      "exact_answer": [
        [
          "Cysteine"
        ],
        [
          "Defensins"
        ],
        [
          "Disulfides"
        ],
        [
          "Three"
        ],
        [
          "Containing (qualifier)"
        ]
      ],
      "id": "58a9c532396a458e50000002",
      "ideal_answer": "Alpha defensins contain six cysteines, which form three well defined disulfide bridges under oxidizing conditions. All three kinds of defensins have six conserved cysteines. They typically contain six conserved cysteines whose three intramolecular disulfides stabilize a largely β-sheet structure. There are six cysteines in the sequence of mature CFBD peptide,. "
    },
    {
      "exact_answer": [
        [
          "Thalamotomy"
        ],
        [
          "Focused Ultrasound Therapy"
        ],
        [
          "Essential Tremor"
        ],
        [
          "Transcranial approach"
        ],
        [
          "Tremor Adverse Event"
        ],
        [
          "Professional guide"
        ],
        [
          "Guide device"
        ],
        [
          "Unresponsive to Treatment"
        ],
        [
          "Mr. - Title"
        ],
        [
          "Focal"
        ],
        [
          "Magnetic Resonance Imaging"
        ],
        [
          "salicylhydroxamic acid"
        ],
        [
          "Radiologic Technologist - Magnetic Resonance Imaging"
        ],
        [
          "Randomized Controlled Trials as Topic"
        ],
        [
          "Observation Method - Magnetic resonance"
        ],
        [
          "Ophthalmic echography, A-mode"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Patients"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Lesion"
        ],
        [
          "Neuralgia"
        ],
        [
          "Preposition For"
        ],
        [
          "Central Minus"
        ],
        [
          "Noninvasive"
        ],
        [
          "Operative Surgical Procedures"
        ],
        [
          "Treated with"
        ],
        [
          "Changing"
        ],
        [
          "Randomized Controlled Trial (publication)"
        ],
        [
          "Lateral"
        ],
        [
          "Investigates"
        ],
        [
          "Effectiveness"
        ],
        [
          "NOAC protocol"
        ],
        [
          "Unilateral"
        ],
        [
          "Pilot Projects"
        ],
        [
          "Journalist"
        ],
        [
          "Negation"
        ],
        [
          "chronic"
        ],
        [
          "Resistant (qualifier value)"
        ],
        [
          "Conclusion"
        ],
        [
          "Incentives"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Thalamic structure"
        ],
        [
          "Population Mean"
        ],
        [
          "Entire nucleus of thalamus"
        ],
        [
          "Generations"
        ],
        [
          "Connectivity"
        ],
        [
          "Approach"
        ],
        [
          "Performed"
        ],
        [
          "Mental Suffering"
        ],
        [
          "Methods aspects"
        ],
        [
          "Precise"
        ],
        [
          "Obsessive-Compulsive Disorder"
        ],
        [
          "Dominant"
        ],
        [
          "Network"
        ],
        [
          "Management procedure"
        ],
        [
          "Imaging Techniques"
        ],
        [
          "Drugs, Essential"
        ],
        [
          "Target"
        ],
        [
          "Range"
        ],
        [
          "Non-invasive"
        ],
        [
          "Biological Evolution"
        ],
        [
          "Effective"
        ],
        [
          "year"
        ],
        [
          "Study"
        ],
        [
          "Test Method"
        ],
        [
          "Application procedure"
        ],
        [
          "innovativeness"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Hemp fiber"
        ],
        [
          "pharmacotherapeutic"
        ],
        [
          "Empowered"
        ],
        [
          "Health Insurance Portability and Accountability Act"
        ],
        [
          "Bone structure of cranium"
        ],
        [
          "Neurophysiology - biologic function"
        ],
        [
          "Integer +2"
        ],
        [
          "Vitality"
        ],
        [
          "Oral part of ventral posterolateral nucleus"
        ],
        [
          "Mu - greek letter"
        ],
        [
          "Ventrolateral"
        ],
        [
          "Parkinson Disease"
        ],
        [
          "PARKINSON DISEASE (allelic variant)"
        ],
        [
          "Neurosurgical Procedures"
        ],
        [
          "Stat (do immediately)"
        ],
        [
          "Diffusion Tensor Imaging"
        ],
        [
          "Institutional Review Board Approval"
        ],
        [
          "Computer Programming Object"
        ],
        [
          "Abnormally high"
        ],
        [
          "Ventral intermediate nucleus of thalamus"
        ],
        [
          "Uncontrolled"
        ],
        [
          "Infrequent"
        ],
        [
          "Informed Consent"
        ],
        [
          "% proof"
        ],
        [
          "Removing (action)"
        ],
        [
          "Biologic Development"
        ],
        [
          "Tracking"
        ],
        [
          "Neuropathy"
        ],
        [
          "Rhythm"
        ],
        [
          "Representation (action)"
        ],
        [
          "Contralateral"
        ],
        [
          "Opening"
        ]
      ],
      "id": "58846be0e56acf5176000005",
      "ideal_answer": "132 A Randomized, Sham-Controlled Trial of Transcranial Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Trial for the Treatment of Tremor-Dominant, Idiopathic Parkinson Disease. PURPOSE: To use diffusion-tensor (DT) magnetic resonance (MR) imaging in patients with essential tremor who were treated with transcranial MR imaging-guided focused ultrasound lesion inducement to identify the structural connectivity of the ventralis intermedius nucleus of the thalamus and determine how DT imaging changes correlated with tremor changes after lesion inducement.MATERIALS AND METHODS: With institutional review board approval, and with prospective informed consent, 15 patients with medication-refractory essential tremor were enrolled in a HIPAA-compliant pilot study and were treated with transcranial MR imaging-guided focused ultrasound surgery targeting the ventralis intermedius nucleus of the thalamus contralateral to their dominant hand. OBJECT: The authors report different MRI patterns in patients with essential tremor (ET) or obsessive-compulsive disorder (OCD) after transcranial MR-guided focused ultrasound (MRgFUS) and discuss possible causes of occasional MRgFUS failure.METHODS: Between March 2012 and August 2013, MRgFUS was used to perform unilateral thalamotomy in 11 ET patients and bilateral anterior limb capsulotomy in 6 OCD patients; in all patients symptoms were refractory to drug therapy. "
    },
    {
      "id": "58837dd72305cd7e21000003",
      "ideal_answer": "CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. We demonstrate that CARMEN knockdown inhibits cardiac specification and differentiation in cardiac precursor cells independently of MIR-143 and -145 expression, two microRNAs located proximal to the enhancer sequences. Importantly, CARMEN expression was activated during pathological remodeling in the mouse and human hearts, and was necessary for maintaining cardiac identity in differentiated cardiomyocytes. This study demonstrates therefore that CARMEN is a crucial regulator of cardiac cell differentiation and homeostasis. CARMEN exhibits RNA-dependent enhancing activity and is upstream of the cardiac mesoderm-specifying gene regulatory network. One of the most upregulated lncRNAs was a SE-associated lncRNA that was named CARMEN, (CAR)diac (M)esoderm (E)nhancer-associated (N)oncoding RNA. Interestingly, CARMEN interacts with SUZ12 and EZH2, two components of the polycomb repressive complex 2 (PRC2). "
    },
    {
      "exact_answer": "yes",
      "id": "5894597e7d9090f353000004",
      "ideal_answer": "hCG enhanced viability of granulosa-lutein cells through antiapoptosis but not proliferation, because the apoptotic marker of annexin V was decreased, but the proliferative markers of Ki67 and proliferating cell nuclear antigen were not increased. However, as the DOTAP concentration increased from 50 to 800 microM, the apoptotic marker Annexin V and ROS double positive cells increased, suggesting that high dose of DOTAP-generated ROS causes cell apoptosis. The apoptosis of the MSCs was induced by subjecting the cells to OGD conditions for 4 h and was detected by Annexin V/PI and Hoechst 33258 staining. In5 crude extract increased staining with the apoptotic marker Annexin V while no staining of healthy normal cells, i.e., naïve or activated CD4 T-cells, was observed. However, we found decreased sperm concentration, increase of morphologically abnormal spermatozoa and increased binding of apoptotic marker annexin V. At the same time, the expressions of CD105, CD31, and the apoptotic marker of Annexin V were detected through flow cytometry for analyzing the relationship between the expression of cell surface markers and biological behavior. "
    },
    {
      "id": "58a0f95c78275d0c4a000055",
      "ideal_answer": "Prion diseases are protein conformation disorders and neither caused by viroid or virus but is a transmissible particle labeled a prion by Pruisner. Prions are proteins most commonly associated with fatal neurodegenerative diseases in mammals but are also responsible for a number of harmless heritable phenotypes in yeast. The misfolded prion protein forms aggregates and is capable of converting normally folded protein to the misfolded state through direct interaction between the two forms. Prion diseases or transmissible spongiform encephalopathies are fatal neurodegenerative diseases characterized by the aggregation and deposition of the misfolded prion protein in the brain. Several neurodegenerative diseases such as transmissible spongiform encephalopathies, Alzheimer\u0027s and Parkinson\u0027s diseases are caused by the conversion of cellular proteins to a pathogenic conformer. Normal prion protein becomes infectious by a different folding, but the triggers are not known. These states arise when a misfolded form of a protein appears and, rather than be removed by cellular quality control mechanisms, persists. Prions are self-propagating infectious protein isoforms. "
    },
    {
      "id": "58a874c338c171fb5b000003",
      "ideal_answer": "The Drp1 receptor Mff is a major regulator of mitochondrial fission, and its overexpression results in increased fission. whereas Mff overexpression stimulated mitochondrial recruitment of Drp1 accompanied by mitochondrial fission. Overexpression of MFF also increases the interaction between DLP1 and Pex11pβ, which knockdown of MFF, but not Fis1, abolishes. "
    },
    {
      "id": "58962dac78275d0c4a000005",
      "ideal_answer": "Yet the prototype peginesatide was recalled after just 1 year of its widespread use in the USA because of serious side-effects including cases of death. Method characterization was conducted for the EMP-based drug peginesatide concerning specificity, linearity, precision, recovery, stability, ion suppression/enhancement, and limit of detection (LOD, 0.25 ng/mL). PURPOSE: Peginesatide, a long-acting erythropoiesis-stimulating agent, was recalled in February 2013 following reports of serious and sometimes fatal hypersensitivity reactions in dialysis patients who received a first dose. BACKGROUND AND OBJECTIVES: Peginesatide (Omontys) is a novel, synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. The erythropoietin-mimetic peptide (EMP) peginesatide belongs to the group of erythropoiesis-stimulating agents (ESAs) that are prohibited when misused in sports. Peginesatide is a synthetic pegylated homodimer of two cyclic 21-amino acid chains. Epo mimetic peptides have also raised expectations. The erythropoietin analog peginesatide was withdrawn from marketing due to unexpected severe anaphylactic reactions associated with administration of the multi-use formulation. Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. "
    },
    {
      "id": "5883868b2305cd7e21000005",
      "ideal_answer": "Identification of genetic variants associated with alternative splicing using sQTLseekeR. By developing the appropriate metrics, we show that sQTLseekeR compares favorably with existing methods that rely on univariate approaches, predicting variants that behave as expected from mutations affecting splicing. We develop a statistical framework that uses a distance-based approach to compute the variability of splicing ratios across observations, and a non-parametric analogue to multivariate analysis of variance. We implement this approach in the R package sQTLseekeR and use it to analyze RNA-Seq data from the Geuvadis project in 465 individuals. We identify hundreds of single nucleotide polymorphisms (SNPs) as splicing QTLs (sQTLs), including some falling in genome-wide association study SNPs. "
    },
    {
      "id": "58a2ccec60087bc10a000003",
      "ideal_answer": "Presenilin (PS1 or PS2) is the catalytic component of the gamma-secretase complex, which mediates the final proteolytic processing step leading to the Alzheimer\u0027s disease (AD)-characterizing amyloid beta-peptide. Here we describe the association of all four components of the gamma-secretase complex, namely presenilin 1 (PS1)-derived fragments, mature nicastrin, APH-1, and PEN-2, with cholesterol-rich detergent insoluble membrane (DIM) domains of non-neuronal cells and neurons that fulfill the criteria of lipid rafts. The gamma-secretase complex processes substrate proteins within membranes and consists of four proteins: presenilin (PS), nicastrin, Aph-1 and Pen-2. gamma-Secretase is known to contain four major protein constituents: presenilin (PS), nicastrin, Aph-1, and Pen-2, all of which are integral membrane proteins. gamma-Secretase is a membrane-embedded multi-protein complex that catalyzes the final cut of the Alzheimer\u0027s disease-related amyloid precursor protein (APP) to amyloid-beta peptides of variable length (37-43 amino acids) via an unusual intramembrane cleavage. PS harbours the enzymatic activity of the complex, and there are two mammalian PS homologues: PS1 and PS2. Gamma-secretase is a widely expressed multisubunit enzyme complex which is involved in the pathogenesis of Alzheimer disease and hematopoietic malignancies through its aberrant processing of the amyloid precursor protein (APP) and Notch1, respectively. "
    },
    {
      "exact_answer": [
        [
          "HTT gene"
        ],
        [
          "polyglutamine"
        ],
        [
          "Huntington\u0027s Disease Pathway"
        ],
        [
          "Mutation"
        ],
        [
          "Proteins"
        ]
      ],
      "id": "58a3428d60087bc10a00001b",
      "ideal_answer": "Huntington disease (HD; OMIM 143100), a progressive neurodegenerative disorder, is caused by an expanded trinucleotide CAG (polyQ) motif in the HTT gene. Huntington\u0027s disease (HD) is caused by a genetic mutation that results in polyglutamine expansion in the N-terminal regions of huntingtin. Mutations of the huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington\u0027s disease (HD). "
    },
    {
      "exact_answer": [
        [
          "SMIM1 gene"
        ],
        [
          "Vel - Blood Group Systems"
        ],
        [
          "Homozygote"
        ],
        [
          "Open Reading Frames"
        ],
        [
          "Proteins"
        ]
      ],
      "id": "58a872bd38c171fb5b000002",
      "ideal_answer": "A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The SMIM1 protein carries the Vel blood group antigen, and homozygosity for a 17 bp deletion in the coding region of the SMIM1 gene represents the molecular basis of the Vel- blood group phenotype. "
    },
    {
      "exact_answer": [
        [
          "SLC9A6 gene"
        ],
        [
          "Mental Retardation, X-Linked, Syndromic, Christianson Type"
        ],
        [
          "Mutation"
        ],
        [
          "Sodium-Hydrogen Antiporter"
        ],
        [
          "X-linked inheritance"
        ]
      ],
      "id": "5895bc397d9090f35300000b",
      "ideal_answer": "X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic neuropathological changes and related behavioral abnormalities. BACKGROUND: Mutations of SLC9A6 may cause an X-linked clinical syndrome first described by Christianson in 1999 in which affected males exhibited profound intellectual disability, autism, drug-resistant epilepsy, ophthalmoplegia, mild craniofacial dysmorphism, microcephaly, and ataxia. Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. BACKGROUND: Christianson Syndrome, a recently identified X-linked neurodevelopmental disorder, is caused by mutations in the human gene SLC9A6 encoding the recycling endosomal alkali cation/proton exchanger NHE6. CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes. Christianson syndrome (CS) is caused by mutations in SLC9A6 and is characterized by severe intellectual disability, absent speech, microcephaly, ataxia, seizures, and behavioral abnormalities. A Christianson syndrome-linked deletion mutation (∆(287)ES(288)) in SLC9A6 disrupts recycling endosomal function and elicits neurodegeneration and cell death. "
    },
    {
      "id": "587d3873ae41fa4569000002",
      "ideal_answer": "SINEUPs: A new class of natural and synthetic antisense long non-coding RNAs that activate translation. In this review, we will detail the discovery of a new functional class of natural and synthetic antisense lncRNAs that stimulate translation of sense mRNAs. Synthetic SINEUPs may be designed by targeting the antisense sequence to the mRNA of choice representing the first scalable tool to increase protein synthesis of potentially any gene of interest. In summary, SINEUPs represent the first scalable tool to increase synthesis of proteins of interest. Natural SINEUPs suggest that embedded Transposable Elements may represent functional domains in long non-coding RNAs. These molecules have been named SINEUPs since their function requires the activity of an embedded inverted SINEB2 sequence to UP-regulate translation. SINEUPs are modular antisense long non-coding RNAs that increase synthesis of target proteins in cells. We propose SINEUPs as reagents for molecular biology experiments, in protein manufacturing as well as in therapy of haploinsufficiencies. "
    },
    {
      "exact_answer": [
        [
          "ezetimibe"
        ],
        [
          "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
        ],
        [
          "LDL Cholesterol Lipoproteins"
        ],
        [
          "Bezafibrate"
        ],
        [
          "Pravastatin"
        ],
        [
          "Fibrates"
        ],
        [
          "Antilipemic agent"
        ],
        [
          "Patients"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Coronary Arteriosclerosis"
        ],
        [
          "Remnant lipoprotein"
        ],
        [
          "Remnant"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "N not otherwise specified Antibody"
        ],
        [
          "Act Mood - Goal"
        ],
        [
          "Reaching"
        ],
        [
          "Abnormally high"
        ],
        [
          "Risk"
        ],
        [
          "Cardiovascular System Findings Domain"
        ],
        [
          "Dose number:Number:Point in time:^Patient:Quantitative"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Baseline"
        ],
        [
          "Cardiovascular Diseases"
        ],
        [
          "Strong"
        ],
        [
          "Associated with"
        ],
        [
          "courage"
        ],
        [
          "Vitamin B3 Assay"
        ],
        [
          "Money or percentage indicator - Percentage"
        ],
        [
          "Hyperlipidemia"
        ],
        [
          "Body Site Modifier - Lower"
        ],
        [
          "shared attribute"
        ],
        [
          "Use - dosing instruction imperative"
        ],
        [
          "Revascularization - action"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Optimum"
        ],
        [
          "Dosage"
        ],
        [
          "Aggressive course"
        ],
        [
          "comparative study research"
        ],
        [
          "cholesterol absorption"
        ],
        [
          "Goal achieved"
        ],
        [
          "Event"
        ],
        [
          "Conclusion"
        ],
        [
          "Power (Psychology)"
        ],
        [
          "Regression Analysis"
        ],
        [
          "Great extent"
        ],
        [
          "Effectiveness"
        ],
        [
          "Frequent"
        ],
        [
          "Resins, Plant"
        ],
        [
          "objective (goal)"
        ],
        [
          "Clinical Trials"
        ],
        [
          "Component (part)"
        ],
        [
          "Average"
        ],
        [
          "Additional"
        ],
        [
          "IMPACT gene"
        ],
        [
          "Reduction - action"
        ],
        [
          "Drug Evaluation"
        ],
        [
          "per year"
        ],
        [
          "Inhibition"
        ],
        [
          "Decrease"
        ],
        [
          "Medical therapy"
        ],
        [
          "Experimental Result"
        ],
        [
          "Result"
        ],
        [
          "Decreased"
        ],
        [
          "Lower (action)"
        ],
        [
          "Reduced"
        ],
        [
          "Treated with"
        ],
        [
          "Examined"
        ],
        [
          "Factor"
        ],
        [
          "factor A"
        ],
        [
          "Level 1"
        ],
        [
          "Increase"
        ],
        [
          "A-factor (Streptomyces)"
        ],
        [
          "Clinical"
        ],
        [
          "Study"
        ]
      ],
      "id": "589c42b178275d0c4a00003f",
      "ideal_answer": "After maximizing statin dose, ezetimibe was added to reach the LDL cholesterol goal in 34% of patients (n \u003d 734). In conclusion, after maximizing statin dose, the addition of ezetimibe results in a substantial increase in the percentage of patients who reach LDL cholesterol goal, a key component of optimal medical therapy. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial). Using Cox regression analysis, the most significant factors associated with achieving LDL cholesterol goals were lower baseline LDL cholesterol, average statin dose, and ezetimibe use. This study examined which of 2 common lipid-lowering drugs (fibrates and statins) is more effective in patients with remnant lipoproteinemia and if lowering remnant lipoprotein levels can reduce CV risk. RLP-C levels at 1 year of treatment were reduced more by bezafibrate than pravastatin (37% and 25% from baseline, respectively). Bezafibrate therapy decreased RLP-C levels to a greater extent than pravastatin and a decrease in RLP-C level may be associated with a reduction in CV events in patients with high RLP-C levels. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. "
    },
    {
      "id": "58a3196360087bc10a00000b",
      "ideal_answer": "Immune checkpoint inhibitors such as ipilimumab, anti-PD-1 monoclonal antibody (programmed cell death-1), and Indoleamine 2,3-dioxygenase (IDO) inhibitors have shown some promise in this field. Pembrolizumab is a selective humanized IgG4 kappa monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor, an integral component of immune checkpoint regulation in the tumor microenvironment. Checkpoint inhibitors with monoclonal antibodies targeting the CTLA-4 or PD-1 axis have revolutionized treatment in some solid tumors, especially melanoma and lung. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) have shown activity in several tumor types with preliminary data suggesting a relationship between PD-L1 expression and response. In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma. Nivolumab and pembrolizumab target programmed cell death protein 1 (PD-1) receptors and have proven to be superior to ipilimumab alone. The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. T. "
    },
    {
      "exact_answer": [
        [
          "Trichotillomania"
        ],
        [
          "Does pull"
        ],
        [
          "HPD gene"
        ],
        [
          "Hair Diseases"
        ],
        [
          "Disease"
        ]
      ],
      "id": "58a8045860087bc10a000035",
      "ideal_answer": "Trichotillomania (hair pulling disorder, HPD) is characterized by significant psychological distress, childhood-onset, and, in adults, certain cognitive deficits such as inhibitory control. Hair pulling disorder (HPD; trichotillomania) is thought to be associated with significant psychiatric comorbidity and functional impairment. TRICHOTILLOMANIA (HAIR PULLING DISORDER). "
    },
    {
      "id": "587f857b8ce3255b64000001",
      "ideal_answer": "Raxibacumab, an IgG1 monoclonal antibody, binds the protective antigen (PA) of Bacillus anthracis, thus blocking toxin effects and leading to improved survival in the rabbit and monkey models of inhalational anthrax. We showed previously in a 96-h sedated canine model that raxibacumab, a monoclonal antibody against protective antigen, augmented hemodynamic support (HS) and improved survival with lethal toxin challenge. With the only anthrax toxin inhibiting therapy (protective antigen-targeting with a monoclonal antibody, raxibacumab) approved to treat inhalational anthrax, the situation, in our view, is still insecure. Blocking the activity of the toxins with raxibacumab, a fully-human mAb directed against the protective antigen of Bacillus anthracis, may serve as an adjunct treatment. Antibiotics can control B. anthracis bacteremia, whereas raxibacumab binds PA and blocks lethal toxin effects. Raxibacumab is the first monoclonal antitoxin antibody made available that can be used with the antibiotics recommended for treatment of the disease. Raxibacumab is a human IgG1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin. "
    },
    {
      "id": "5880acbb0a76a87357000003",
      "ideal_answer": "Exonic splice enhancers are one of the principle non-splice site motifs. Four high-throughput studies have provided a compendium of motifs that function as exonic splice enhancers, but only one, RESCUE-ESE, has been generally employed to examine the properties of enhancers. In humans, much of the information specifying splice sites is not at the splice site. "
    },
    {
      "exact_answer": "yes",
      "id": "58a6b98860087bc10a000028",
      "ideal_answer": "SUMOylation, the conjugation of target proteins with SUMO (small ubiquitin-related modifier), is a type of post-translational modification in eukaryotes and involves the sequential action of activation (E1), conjugation (E2) and ligation (E3) enzymes. SUMOylation, the covalent attachment of a member of the small ubiquitin-like modifier (SUMO) family of proteins to lysines in target substrates, is an essential post-translational modification in eukaryotes. Sumoylation is a post-translational modification essential in most eukaryotes that regulates stability, localization, activity, or interaction of a multitude of proteins. SUMOylation is an essential post-translational modification that regulates a variety of cellular processes including cell cycle progression. Although the SUMOylation pathway has been identified and investigated in many eukaryotes, the mechanisms of SUMOylation in regulating the functions of various substrates are still poorly understood. Post-translational modification by SUMO is a highly conserved pathway in eukaryotes that plays very important regulatory roles in many cellular processes. One way plants achieve this is through post-translational modification of target proteins by ubiquitination and SUMOylation. Plants have evolved to cope with changing environmental conditions. "
    },
    {
      "exact_answer": [
        [
          "GORAB gene"
        ],
        [
          "clobutinol"
        ],
        [
          "Opioids"
        ],
        [
          "Market"
        ],
        [
          "Negation"
        ],
        [
          "sibutramine"
        ],
        [
          "orlistat"
        ],
        [
          "ethyl ether"
        ],
        [
          "valdecoxib"
        ],
        [
          "Withdrawal (dysfunction)"
        ],
        [
          "rofecoxib"
        ],
        [
          "Increase"
        ],
        [
          "Cardiovascular system"
        ],
        [
          "KCNA4 gene"
        ],
        [
          "N not otherwise specified Antibody"
        ],
        [
          "KCNH2 gene"
        ],
        [
          "Antitussive Agents"
        ],
        [
          "Risk"
        ],
        [
          "Withdraw (activity)"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Sales - occupational activity"
        ],
        [
          "Singular"
        ],
        [
          "shared attribute"
        ],
        [
          "Writing (function)"
        ],
        [
          "Cardiac Arrhythmia"
        ],
        [
          "Counter Device Component"
        ],
        [
          "Code"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Europe"
        ],
        [
          "Blocking"
        ],
        [
          "Excess"
        ],
        [
          "Removed"
        ],
        [
          "Obesity"
        ],
        [
          "United States"
        ],
        [
          "Cardiovascular event"
        ],
        [
          "Death Related to Adverse Event"
        ],
        [
          "Serious"
        ],
        [
          "Relationships"
        ],
        [
          "Induce (action)"
        ],
        [
          "incidence of cases"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Genes"
        ],
        [
          "Current (present time)"
        ],
        [
          "Potential"
        ],
        [
          "Time"
        ],
        [
          "Drugs, Non-Prescription"
        ]
      ],
      "id": "58a326da60087bc10a00000e",
      "ideal_answer": "A common over-the-counter (OTC) non-opioid antitussive drug, clobutinol, was recently withdrawn from the market due to its potential to induce cardiac arrhythmias by a blockade of the potassium channel coded by the human ether-à-go-go-related gene (hERG). However, despite this, at the time of writing orlistat (Europe; USA) remains the only drug currently marketed for the treatment of obesity, with sibutramine having recently been withdrawn from sale globally due to the increased incidence of serious, non-fatal cardiovascular events. rofecoxib was voluntarily removed from the market for increased cardiovascular risk and in April 2005, valdecoxib was also withdrawn, at least in part, due to excess cardiovascular risk. n. "
    },
    {
      "id": "58a9cd03396a458e50000003",
      "ideal_answer": "Human telomeres are associated with the shelterin complex which consists of six telomere-associated proteins that specifically bind to telomeric DNA. In human, the shelterin complex binds TTAGGG DNA repeats and provides capping to chromosome ends. Telomeres interact with numerous proteins, including components of the shelterin complex, whose alteration, similarly to proliferation-induced telomere shortening, initiates cellular senescence. Telomeres need to be protected by the shelterin complex to avoid junctions occurring between chromosomes while failing topoisomerases or clustered DNA damage processing may produce double-strand breaks, thus requiring swift repair to avoid cell death. Alterations or removal of individual shelterin components would lead to telomere uncapping and telomere dysfunction, resulting in cellular senescence and transformation to a malignant state. Telomere repeat binding factor TRF2 is a member of shelterin complex with an important role in protecting and stabilizing chromosomal ends. Telomeres, repetitive DNA sequences at chromosome ends, are shielded against the DNA damage response (DDR) by the shelterin complex. A multiprotein complex known as shelterin prevents recognition of telomeric sequences as sites of DNA damage. Shelterin Protects Chromosome Ends by Compacting Telomeric Chromatin. "
    },
    {
      "exact_answer": [
        [
          "SPAG5 gene"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "P Blood group antibodies"
        ],
        [
          "Malignant neoplasm of breast"
        ],
        [
          "Cohort"
        ],
        [
          "Taxol"
        ],
        [
          "hydroxyethyl starch 130-0.4"
        ],
        [
          "Transcript"
        ],
        [
          "P prime"
        ],
        [
          "Cervix carcinoma"
        ],
        [
          "Arabic numeral 68"
        ],
        [
          "Anthracycline Antibiotics"
        ],
        [
          "Abnormally high"
        ],
        [
          "Continuance of life"
        ],
        [
          "Cancer Survivorship Research"
        ],
        [
          "Statistical sensitivity"
        ],
        [
          "Overall Publication Type"
        ],
        [
          "Breast"
        ],
        [
          "Disease Progression"
        ],
        [
          "Associated with"
        ],
        [
          "Estrogen receptor negative"
        ],
        [
          "Experimental Result"
        ],
        [
          "Proteins"
        ],
        [
          "Chemotherapy Regimen"
        ],
        [
          "Prognosis bad"
        ],
        [
          "Oncogenes"
        ],
        [
          "Automobile Driving"
        ],
        [
          "Copy Number"
        ],
        [
          "Aberrant"
        ],
        [
          "Identified"
        ],
        [
          "Predictor"
        ],
        [
          "1+ Score, WHO"
        ],
        [
          "Did not receive therapy or drug for"
        ],
        [
          "Cytotoxic Chemotherapy"
        ],
        [
          "1+ Score"
        ],
        [
          "Patients"
        ],
        [
          "Numerous"
        ],
        [
          "Cancer Progression"
        ],
        [
          "Comparison"
        ],
        [
          "Receive"
        ],
        [
          "Expression procedure"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Direct (qualifier)"
        ],
        [
          "Target"
        ],
        [
          "Mental concentration"
        ],
        [
          "Reduced"
        ],
        [
          "NDUFS7 gene"
        ],
        [
          "KIF23 gene"
        ],
        [
          "Increase"
        ],
        [
          "mTOR Signaling Pathway BioCarta"
        ],
        [
          "POLQ gene"
        ],
        [
          "protein expression"
        ],
        [
          "NDUFS4 gene"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Lower - spatial qualifier"
        ],
        [
          "Death Adverse Event Due to Disease Progression Not Associated with More Specific CTCAE Term"
        ],
        [
          "Clinical"
        ],
        [
          "Arabic numeral 23"
        ],
        [
          "Arabic numeral 97"
        ],
        [
          "ATRX wt Allele"
        ],
        [
          "Negation"
        ],
        [
          "Up-Regulation (Physiology)"
        ],
        [
          "Utilities (organization)"
        ],
        [
          "Taxanes"
        ],
        [
          "Integer +2"
        ],
        [
          "Gleason Grading System"
        ],
        [
          "BRCA2 wt Allele"
        ],
        [
          "Protein concentration, test strip measurement"
        ],
        [
          "Adoptive Immunotherapy"
        ],
        [
          "Neoadjuvant Therapy"
        ],
        [
          "MTOR gene"
        ],
        [
          "Relapsing course"
        ],
        [
          "Relate - vinyl resin"
        ],
        [
          "Xenograft type of graft"
        ],
        [
          "suggestion"
        ],
        [
          "Arrested progression"
        ],
        [
          "Analysis Dataset Domain"
        ],
        [
          "Independence"
        ],
        [
          "Genomics"
        ],
        [
          "PSA Failure"
        ],
        [
          "Generic Role"
        ],
        [
          "Chromosome Segregation"
        ],
        [
          "Hazard Ratio"
        ],
        [
          "mitotic spindle organization in nucleus"
        ],
        [
          "1/2"
        ],
        [
          "Malignant neoplasm of lung"
        ],
        [
          "Malignant neoplasm of prostate"
        ],
        [
          "Secondary malignant neoplasm of lymph node"
        ],
        [
          "Neoplasm Metastasis"
        ],
        [
          "Act Code - General"
        ],
        [
          "combination of objects"
        ],
        [
          "Distant"
        ],
        [
          "physiologic migration"
        ],
        [
          "Microarray"
        ],
        [
          "Microarray Analysis"
        ],
        [
          "Gene Amplification Abnormality"
        ],
        [
          "Entire pelvic lymph node"
        ],
        [
          "Participation"
        ],
        [
          "Cardiac Arrest"
        ],
        [
          "Chemotherapy, Adjuvant"
        ]
      ],
      "id": "5884fe4ce56acf5176000010",
      "ideal_answer": "BACKGROUND: We conducted multiple microarray datasets analyses from clinical and xenograft tumor tissues to search for disease progression-driving oncogenes in prostate cancer (PCa). In multivariable analysis, high SPAG5 transcript and SPAG5 protein expression were associated with reduced breast cancer-specific survival at 10 years compared with lower concentrations (Uppsala: HR 1·62, 95% CI 1·03-2·53, p\u003d0·036; METABRIC: 1·27, 1·02-1·58, p\u003d0·034; untreated lymph node-negative cohort: 2·34, 1·24-4·42, p\u003d0·0090; and Nottingham-HES: 1·73, 1·23-2·46, p\u003d0·0020). Copy number aberration leading to SPAG5 gain or amplification and high SPAG5 transcript and SPAG5 protein concentrations were associated with shorter overall breast cancer-specific survival (METABRIC cohort [copy number aberration]: hazard ratio [HR]1·50, 95% CI 1·18-1·92, p\u003d0·00010; METABRIC cohort [transcript]: 1·68, 1·40-2·01, p\u003c0·0001; and Nottingham-HES-breast cancer cohort [protein]: 1·68, 1·32-2·12, p\u003c0·0001). Multivariable analysis showed high SPAG5 transcript concentrations to be independently associated with longer distant relapse-free survival after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD Anderson-NeoACT: HR 0·68, 95% CI 0·48-0·97, p\u003d0·031). In patients with oestrogen receptor-negative breast cancer with high SPAG5 protein expression, anthracycline-based adjuvant chemotherapy increased breast cancer-specific survival overall compared with that for patients who did not receive chemotherapy (Nottingham-oestrogen receptor-negative-ACT cohort: HR 0·37, 95% CI 0·20-0·60, p\u003d0·0010). "
    },
    {
      "id": "587e2a0cc32c812009000001",
      "ideal_answer": "Path2PPI: an R package to predict protein-protein interaction networks for a set of proteins. We introduce Path2PPI, a new R package to identify protein-protein interaction (PPI) networks for fully sequenced organisms for which nearly none PPI are known. Path2PPI predicts PPI networks based on sets of proteins from well-established model organisms, providing an intuitive visualization and usability. It can be used to combine and transfer information of a certain pathway or biological process from several reference organisms to one target organism. "
    },
    {
      "id": "589ae59c78275d0c4a000036",
      "ideal_answer": "US FDA approved Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, Oseltamivir is the only first line defense drug available for the treatment of Swine Flu. Oseltamivir was the first orally active neuraminidase inhibitor commercially developed by US based Gilead Sciences and is currently marketed by F. Hoffmann-La Roche (Roche). The latter is the binding cavity for 3 currently used neuraminidase inhibitors: oseltamivir (Tamiflu), zanamivir (Relenza) and peramivir; thus, the drugs should remain effective for treatment. Though therapeutic dose of oseltamivir was given as antiviral treatment for the early therapy, and other therapeutic measures such as energetic respiratory and circulatory support, and immunosuppressant therapy were given. Oseltamivir (has known by its brand name \u0027Tamiflu\u0027) is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. Oseltamivir is an antiviral drug which works by blocking the function of the viral neuraminidase protein. All patients were given specific antiviral therapy (oseltamivir). "
    },
    {
      "id": "58a5d7ef60087bc10a000026",
      "ideal_answer": "Desomorphine is the semi-synthetic opioid claimed to be the main component of krokodil. Desomorphine is an opioid misused as \"crocodile\", a cheaper alternative to heroin. "
    },
    {
      "exact_answer": [
        [
          "Gilles de la Tourette syndrome"
        ],
        [
          "SLITRK1 gene"
        ],
        [
          "Histidine Decarboxylase"
        ],
        [
          "Histamine"
        ],
        [
          "Staphylococcal Protein A"
        ],
        [
          "Slitting"
        ],
        [
          "Enzymes"
        ],
        [
          "Variant"
        ],
        [
          "Etiology aspects"
        ],
        [
          "Histidine"
        ],
        [
          "3\u0027 Untranslated Regions"
        ],
        [
          "Mutation"
        ],
        [
          "Genes"
        ],
        [
          "1+ Score"
        ],
        [
          "Infrequent"
        ],
        [
          "histamine biosynthetic process"
        ],
        [
          "Rating (action)"
        ],
        [
          "Encode (action)"
        ],
        [
          "enzyme biosynthesis"
        ],
        [
          "Genetic"
        ],
        [
          "findings aspects"
        ],
        [
          "Leading"
        ],
        [
          "Rare"
        ],
        [
          "Limited (extensiveness)"
        ],
        [
          "Function"
        ],
        [
          "BGLAP gene"
        ],
        [
          "HDC gene"
        ],
        [
          "Homo sapiens"
        ],
        [
          "physiopathological"
        ],
        [
          "Tic disorder"
        ],
        [
          "Informing patient"
        ],
        [
          "Singular"
        ],
        [
          "Inspiration function"
        ],
        [
          "Mus"
        ],
        [
          "genetic pedigree"
        ],
        [
          "Stimulator"
        ],
        [
          "neurite outgrowth"
        ],
        [
          "miRNA binding"
        ],
        [
          "Generic Role"
        ],
        [
          "Retinoic Acid Response Element"
        ],
        [
          "Generations"
        ],
        [
          "Rodent"
        ],
        [
          "Histamine Production"
        ],
        [
          "Gene Deletion Abnormality"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Science of Anatomy"
        ],
        [
          "genetic linkage analysis"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Similarity"
        ],
        [
          "Changing"
        ],
        [
          "Scientific Study"
        ],
        [
          "Support, device"
        ],
        [
          "Possibly Related to Intervention"
        ],
        [
          "Parallel Lesion"
        ],
        [
          "Deficiency of carboxy-lyase"
        ],
        [
          "deficiency aspects"
        ],
        [
          "Spectrum"
        ],
        [
          "Base"
        ],
        [
          "Gene Mutation"
        ],
        [
          "Variation (Genetics)"
        ],
        [
          "Onset of (contextual qualifier)"
        ],
        [
          "Hypothesis"
        ],
        [
          "Identification (Psychology)"
        ],
        [
          "Research Activities"
        ],
        [
          "Regulation"
        ],
        [
          "Human Characteristics"
        ],
        [
          "Genetic syndrome"
        ],
        [
          "Relationship by association"
        ],
        [
          "Site"
        ],
        [
          "Previous"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Formation"
        ],
        [
          "Carboxy-Lyases"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Disease"
        ]
      ],
      "id": "58a7fb2860087bc10a000034",
      "ideal_answer": "Recently, two variants, including a single-base deletion resulting in a truncated protein and a 3\u0027-untranslated-region variant altering a binding site for micro-RNA in the Slit and Trk-like 1 gene, were found to be a genetic cause of Tourette syndrome. A rare genetic form of Tourette syndrome due to L-histidine-decarboxylase mutation, with similar features in human and rodent, has inspired new research on functional anatomy of Tourette syndrome. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. The recent implication of the histamine decarboxylase (HDC) gene, the key enzyme in histamine production, raises the intriguing hypothesis of a possible role of histaminergic dysfunction leading to TS onset. A mutation in histidine decarboxylase (Hdc), the key enzyme for the biosynthesis of histamine (HA), has been implicated as a rare genetic cause. we describe an analysis of linkage in a two-generation pedigree leading to the identification of a rare functional mutation in the HDC gene encoding L-histidine decarboxylase, the rate-limiting enzyme in histamine biosynthesis. The SLITRK1 gene encodes a developmentally regulated stimulator of neurite outgrowth and previous studies have implicated rare variants in this gene in disorders in the OC spectrum, specifically Tourette syndrome (TS). "
    },
    {
      "exact_answer": "yes",
      "id": "588fa4b9ed9bbee70d000006",
      "ideal_answer": "Ocrelizumab is the first treatment with positive results in the primarily progressive forms and tocilizumab, a drug product for rheumatoid arthritis, stands out as a potential candidate for the treatment of neuromyelitis optica. The efficacy of three of them, rituximab, ocrelizumab and ofatumumab in MS has been confirmed by placebo-controlled clinical trials demonstrating a significant reduction of the annualized relapsing rate (ARR), new gadolinium-enhancing (GdE) and T2 lesions. Expert commentary: The recent encouraging results of the ocrelizumab trial in PP MS, the first to reach the primary disability endpoint, indicate B cells as a promising therapeutic target to prevent disease progression. Ongoing PMS trials are currently being conducted with the phosphodiesterase inhibitor ibudilast, S1P modulator siponimod and anti-B-cell therapy ocrelizumab. RECENT FINDINGS: Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-β-1a, and three times weekly glatiramer acetate. Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis. Advances made in immunomodulation are driving the progress being made in the treatment of MS. "
    },
    {
      "exact_answer": [
        [
          "DNA Microarray Chip"
        ],
        [
          "Gap Junctions"
        ],
        [
          "Comprehensive"
        ],
        [
          "Mace extract"
        ],
        [
          "Data"
        ],
        [
          "Discover"
        ],
        [
          "Polymerase Chain Reaction"
        ],
        [
          "DNA-Binding Proteins"
        ],
        [
          "Peak level"
        ],
        [
          "research study"
        ],
        [
          "Design"
        ],
        [
          "Methods"
        ],
        [
          "Nexus (resin cement)"
        ],
        [
          "literary novel"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Duplicate"
        ],
        [
          "Positioning Attribute"
        ],
        [
          "Make - Instruction Imperative"
        ],
        [
          "Bar Codes"
        ],
        [
          "Inference"
        ],
        [
          "Computer program package"
        ],
        [
          "Specimen Source Codes - Quality Control"
        ],
        [
          "Drosophila melanogaster"
        ],
        [
          "Call (Instruction)"
        ],
        [
          "Width"
        ],
        [
          "Apply (instruction)"
        ],
        [
          "Analysis of substances"
        ],
        [
          "allowing"
        ],
        [
          "Availability of"
        ],
        [
          "Random"
        ],
        [
          "regional"
        ],
        [
          "Bilateral"
        ],
        [
          "Protection"
        ],
        [
          "removal technique"
        ],
        [
          "Cultured Cell Line"
        ],
        [
          "Estimated"
        ],
        [
          "Resolution"
        ],
        [
          "Efficient"
        ],
        [
          "transcription factor binding"
        ],
        [
          "Application procedure"
        ],
        [
          "pattern binding"
        ],
        [
          "Aim (idea)"
        ],
        [
          "Site"
        ],
        [
          "Test Method"
        ],
        [
          "Binding (Molecular Function)"
        ],
        [
          "Possible diagnosis"
        ],
        [
          "Performed"
        ],
        [
          "Increase"
        ]
      ],
      "id": "5883bce3e56acf5176000003",
      "ideal_answer": "Furthermore, we developed bespoke methods to estimate the width of the protected region resulting from protein-DNA binding and to infer binding positions from ChIP-nexus data. We describe a peak caller PeakXus that is specifically designed to leverage the increased resolution of ChIP-exo/Nexus and developed with the aim of making as few assumptions of the data as possible to allow discoveries of novel binding patterns. PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments. Here, we present a comprehensive software package for ChIP-nexus data that exploits the random barcodes for selective removal of PCR duplicates and for quality control. Finally, we applied our peak calling method as well as the two other methods MACE and MACS2 to the available ChIP-nexus data. We apply PeakXus to ChIP-Nexus and ChIP-exo experiments performed both in Homo sapiens and in Drosophila melanogaster cell lines. Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus. "
    },
    {
      "exact_answer": [
        [
          "Greek letter tau"
        ],
        [
          "Neurofibrillary degeneration (morphologic abnormality)"
        ],
        [
          "Alzheimer\u0027s Disease Pathway KEGG"
        ],
        [
          "Polymerization"
        ],
        [
          "Negation"
        ],
        [
          "Aggregate"
        ],
        [
          "Tauopathies"
        ],
        [
          "Neuronal loss"
        ],
        [
          "Microtubule-Associated Protein Tau"
        ],
        [
          "microtubule binding"
        ],
        [
          "Glycogen Synthase Kinases"
        ],
        [
          "Microtubules"
        ],
        [
          "Formation"
        ],
        [
          "Affinity"
        ],
        [
          "YWHAQ gene"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Decreased"
        ],
        [
          "MAPT gene"
        ],
        [
          "Presenile dementia"
        ],
        [
          "Anabolism"
        ],
        [
          "Unmarried"
        ],
        [
          "Pick Disease of the Brain"
        ],
        [
          "Nucleated"
        ],
        [
          "victim"
        ],
        [
          "Senile Plaques"
        ],
        [
          "Manufactured form"
        ],
        [
          "Comprehension"
        ],
        [
          "Entire dentate gyrus"
        ],
        [
          "paired helical filament"
        ],
        [
          "Generic Role"
        ],
        [
          "Axon"
        ],
        [
          "Generations"
        ],
        [
          "Rating (action)"
        ],
        [
          "Links List"
        ],
        [
          "Initiate (source type)"
        ],
        [
          "combination of objects"
        ],
        [
          "Subgroup"
        ],
        [
          "Autopsy"
        ],
        [
          "The science and art of healing"
        ],
        [
          "Neurodegenerative Disorders"
        ],
        [
          "Amyloid beta-Peptides"
        ],
        [
          "Instability"
        ],
        [
          "Pathologic"
        ],
        [
          "Pathologic Processes"
        ],
        [
          "Dendritic"
        ],
        [
          "Alteration"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Inclusion"
        ],
        [
          "glutamate metabolic process"
        ],
        [
          "Abnormal degeneration"
        ],
        [
          "Traumatic Brain Injury"
        ],
        [
          "cytotoxicity"
        ],
        [
          "Decade"
        ],
        [
          "Similarity"
        ],
        [
          "Mice, Transgenic"
        ],
        [
          "Consequence of"
        ],
        [
          "Widespread"
        ],
        [
          "Device Display Device Component"
        ],
        [
          "Assembly (group of parts)"
        ],
        [
          "Changed status"
        ],
        [
          "Causing"
        ],
        [
          "status - In progress"
        ],
        [
          "Dietary Lead"
        ],
        [
          "Patient observation"
        ],
        [
          "Peptides"
        ],
        [
          "Pathological aspects"
        ],
        [
          "Contain (action)"
        ],
        [
          "Impaired"
        ],
        [
          "Neuronal"
        ],
        [
          "Effectiveness"
        ],
        [
          "month"
        ],
        [
          "Biological Markers"
        ],
        [
          "strategy"
        ],
        [
          "Involvement with"
        ],
        [
          "Double Value Type"
        ],
        [
          "Comparison"
        ],
        [
          "Good"
        ],
        [
          "Functional Relationship"
        ],
        [
          "Decrease"
        ],
        [
          "Site"
        ],
        [
          "Brain"
        ],
        [
          "Reduced"
        ],
        [
          "Evidence of"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Increased"
        ]
      ],
      "id": "58a2efec60087bc10a000008",
      "ideal_answer": "The formation of neurofibrillary tangles from the assembly of hyperphosphorylated tau leads to dendritic and axonal instability, synaptic degeneration, and neuronal loss. The pathological hallmarks of Alzheimer\u0027s disease (AD)--widespread synaptic and neuronal loss and the pathological accumulation of amyloid-beta peptide (Aβ) in senile plaques, as well as hyperphosphorylated tau in neurofibrillary tangles--have been known for many decades, but the links between AD pathology and dementia and effective therapeutic strategies remain elusive. Pseudophosphorylation of tau decreases its affinity for microtubules, and pseudohyperphosphorylated forms of tau do not have significantly decreased levels of microtubule binding as compared to single and double sites. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer\u0027s disease and also explain the potentially beneficial role of tau polymerization and NFT formation. Neurofibrillary tangles (NFTs), a marker of neuronal alterations in Alzheimer\u0027s disease (AD) and other tauopathies, are comprised of aggregates of hyperphosphorylated tau protein. However, the functional consequences of hyperphosphorylation on the microtubule binding and polymerization of tau are not well understood. "
    },
    {
      "id": "58a5d54860087bc10a000025",
      "ideal_answer": "They presented with limp, and an elaborate panel of tests and procedures were undertaken before the diagnosis of scurvy was made. Scurvy, or \"Barlow\u0027s disease\", is a widely described disease involving cutaneous and mucosal lesions resulting from vitamin C deficiency. Treatment with vitamin C led to rapid recovery of symptoms. "
    },
    {
      "exact_answer": [
        [
          "Homo sapiens"
        ],
        [
          "DEFA5 gene"
        ],
        [
          "HDAC5 wt Allele"
        ],
        [
          "Defensins"
        ],
        [
          "Peptides"
        ]
      ],
      "id": "58a9c152396a458e50000001",
      "ideal_answer": "The major tissue in which HD5 is expressed is the crypt of the small intestine, an anaerobic niche that should allow for substantial pools of both oxidized and (partly) reduced HD5. Human enteric α-defensins (HD5 and HD6), major antimicrobial peptides produced by Paneth cells in the intestine, play important roles in intestinal innate immunity. Human α-defensin 5 (HD5) is a 32-residue cysteine-rich host-defense peptide that exhibits broad-spectrum antimicrobial activity and contributes to innate immunity in the human gut and other organ systems. Human α-defensin 5 (HD5) exhibits broad spectrum antimicrobial activity and plays an important role in mucosal immunity of the small intestine. Human α-defensin 5 (HD5), the most abundant enteric antimicrobial peptide,. Human α-defensin 5 (HD5) is an innate immune effector peptide secreted by epithelial cells in the genitourinary tract. The concentrations of lactoferrin and defensins in preterm breast milk have antimicrobial activity against common neonatal pathogens. HD5, naturally present at very high concentrations in the mucosa of the small intestine,. "
    },
    {
      "id": "5891869b621ea6ff7e00000c",
      "ideal_answer": "Eteplirsen (Exondys 51) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics. We also assessed the effect of dystrophin restoration on the expression of the five dystromirs in serum of DMD patients treated systemically for 12 weeks with antisense oligomer eteplirsen that induces skipping of exon 51 in the dystrophin gene. Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping. OBJECTIVE: In prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51. Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen. The first AON (eteplirsen) has recently received accelerated approval by the Food and Drug Administration in the US. "
    },
    {
      "exact_answer": [
        [
          "Codon Genus"
        ],
        [
          "Usage"
        ],
        [
          "Inca"
        ],
        [
          "Synonym"
        ],
        [
          "Analysis of substances"
        ]
      ],
      "id": "5891c90949702f2e01000001",
      "ideal_answer": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map. In addition to computing codon frequencies and several usage indices, such as \u0027codon bias\u0027, effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons. "
    },
    {
      "exact_answer": "yes",
      "id": "58a5b01760087bc10a000023",
      "ideal_answer": "Because the Nox5 gene is absent in rodents, we generated transgenic mice expressing human Nox5 in a podocyte-specific manner (Nox5(pod+)). But there are exceptions; for example rodents lack NOX5 and Caenorhabditis elegans expresses only DUOXes. The NADPH oxidase 5 (NOX5) gene is present in humans but not rodents. The data document that the NOX5 gene was expressed in cells of lagomorphs unlike rodents, making the rabbit an interesting model to study NOX5 functions. Nox5 was lost in rodents, and Nox3, which functions in the inner ear in gravity perception, emerged the most recently, corresponding to full-time adaptation of vertebrates to land. NOX expression patterns in animals are complex and ancestral NOXes, NOX5-like isoforms and DUOXes are generally found. "
    },
    {
      "id": "58a3264e60087bc10a00000d",
      "ideal_answer": "The results implicate the cis-enedial reactive metabolite of DIOB was responsible for the observed toxicities. The observed modest depletion of hepatic GSH in DIOB-treated animals suggests the actions of one or more reactive metabolites, and the hepatic injury observed could be due at least in part to reactions of these metabolites with crucial biomolecules. Cytochrome P450 3A enzymes are implicated in DIOB-induced hepatotoxicities by catalyzing the formation of the reactive metabolite of DIOB. . The neurotoxicity of endosulfan and its metabolites is closely related to oxidative damage and antioxidative deficit. Our data from this study strongly indicate that Dic as well as its metabolites could be involved in the hepato-toxic action through inhibition of ATP synthesis. "
    },
    {
      "exact_answer": "yes",
      "id": "58a957a8cc344ae31e000001",
      "ideal_answer": "vitamin D induces autophagy. Vitamin D shows promise for the prevention and amelioration of pathologic responses in IBD, an effect that is mediated, at least in part, by the induction and modulation of autophagy. Autophagy signaling pathway was regulated by vitamin D3. 1,25(OH)2D treatment was accompanied by autophagy activation. "
    },
    {
      "id": "5895b9ae7d9090f35300000a",
      "ideal_answer": "Athelia is a very rare entity that is defined by the absence of the nipple-areola complex. The absence of nipple-areola complex is a rare entity and is always associated with other anomalies. Absence of the nipple, areola (athelia), or the breast tissue (amastia) is less frequent. This paper described a case of bilateral athelia without other alterations. "
    },
    {
      "exact_answer": "yes",
      "id": "5896399978275d0c4a00000b",
      "ideal_answer": "Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in ≥30% of human melanomas and was associated with reduced patient survival. Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer. "
    },
    {
      "exact_answer": [
        [
          "dopamine transporter"
        ],
        [
          "Minisatellite Repeats"
        ],
        [
          "Attention deficit hyperactivity disorder"
        ],
        [
          "SLC6A3 gene"
        ],
        [
          "Exons"
        ]
      ],
      "id": "58a2ced760087bc10a000004",
      "ideal_answer": "In 29 adults with attention deficit hyperactivity disorder (ADHD) striatal dopamine transporter (DAT) availability was assessed by [(99m)Tc]TRODAT-1 SPECT and correlated with 3\u0027 VNTR polymorphism of the DAT gene on chromosome 5p15.3. The locus of the solute carrier 6A3 (SLC6A3; dopamine transporter 1; DAT1) localizes to 5p15.33; the gene has repeatedly been implicated in the etiology of ADHD. The gene encoding DAT1 consists of 15 exons spanning 60 kb on chromosome 5p15.32. "
    },
    {
      "id": "58a3275960087bc10a00000f",
      "ideal_answer": "Maternal-fetal transmission of Zika virus has been documented; evidence suggests that congenital Zika virus infection is associated with microcephaly and other adverse pregnancy and infant outcomes. Recent studies have reported an increase in the number of fetuses and neonates with microcephaly whose mothers were infected with the Zika virus (ZIKV) during pregnancy. "
    },
    {
      "exact_answer": "yes",
      "id": "58a93877ee23e0236b000001",
      "ideal_answer": "The morphogen Nodal was proposed to form a long-range signaling gradient via a reaction-diffusion system, on the basis of differential diffusion rates of Nodal and its antagonist Lefty. as well as the expression of Lefty, an inhibitor of nodal signaling,. The expression of lefty, an inhibitor of nodal is often reduced in tumor cells. Nodal, and an inhibitor, Lefty. he Nodal inhibitor lefty. "
    }
  ]
}